The disclosed embodiments include lenses, devices and methods for changing or controlling the wavefront of light entering an eye, in particular a human eye.
Particular disclosed embodiments include lenses, devices and methods for mitigating/addressing ocular refractive error, in particular in human eyes. The ocular refractive error may for example arise from myopia or hyperopia, with or without astigmatism. The ocular refractive error may arise from presbyopia, either alone or in combination with myopia or hyperopia and with or without astigmatism.
The disclosed embodiments of lenses, devices and methods include embodiments that address foveal vision and embodiments that address both foveal and peripheral vision.
Examples of lenses in the fields of the disclosed embodiments include contact lenses, corneal onlays, corneal inlays, and lenses for intraocular devices (both anterior and posterior chamber).
Examples of devices in the fields of the disclosed embodiments include accommodating intraocular lenses and electro-active spectacle lenses.
Examples of methods in the fields of the disclosed embodiments include methods of changing the refractive state/wavefront of light entering an eye and received by a retina of the eye (e.g. refractive surgery, corneal ablation), methods of design and/or manufacture of lenses and optical devices, methods of surgery to alter the refractive state of an eye and methods of controlling stimulus for progression of eye growth.
For an image to be perceived clearly, the optics of the eye should result in an image that is focused on the retina. Myopia, commonly known as short-sightedness, is an optical disorder of the eye wherein on-axis images are focused in front of the fovea of the retina. Hyperopia, commonly known as long-sightedness, is an optical disorder of the eye wherein on-axis images are focused behind the fovea of the retina. The focusing of images in front of or behind the fovea of the retina creates a lower order aberration of defocus. Another lower order aberration is astigmatism. An eye may also have higher order optical aberrations, including for example spherical aberration, coma and/or trefoil. Many people experiencing natural refractive error are progressing (the refractive error is increasing over time). Progression is particularly widespread in people with myopia. Schematic representations of eyes exhibiting myopia or hyperopia and astigmatism are shown in
At birth human eyes are hyperopic, i.e. the axial length of the eyeball is too short for its optical power. With age, from infancy to adulthood, the eyeball continues to grow until its refractive state stabilizes. Elongation of the eye in a growing human may be controlled by a feedback mechanism, known as the emmetropisation process, so that the position of focus relative to the retina plays a role in controlling the extent of eye growth. Deviation from this process would potentially result in refractive disorders like myopia, hyperopia and/or astigmatism. While there is ongoing research into the cause of deviation of emmetropisation from stabilising at emmetropia, one theory is that optical feedback can provide a part in controlling eye growth. For example,
A number of optical device designs and refractive surgery methods have been proposed to control the growth of the eye during emmetropisation. Many are generally based on refinements to the idea summarised above that foveal imagery provides a stimulus that controls the growth of the eye. In humans, the eye grows longer during emmetropisation and can not grow shorter. Accordingly, during emmetropisation an eye may grow longer to correct for hyperopia, but it can not grow shorter to correct for myopia. Many proposals have been made for addressing myopia progression, some of which are summarised below.
U.S. Pat. No. 6,752,499 (Aller) proposes the use of bifocal contact lenses for myopic participants who exhibit near-point esophoria, for providing a stimulus for reducing/controlling myopia progression. U.S. Pat. No. 7,025,460 (Smith et al) proposes the use of corrective eye lenses that shift the focal plane in front of the peripheral retina. U.S. Pat. No. 7,506,983 (To et al) proposes a method of treating myopia progression in human eyes by producing a secondary myopic image by use of Fresnel optics, while correcting the myopia of the candidate via the refractive portion of the lens. U.S. Pat. No. 7,997,725 (Phillips) proposes a method of simultaneous vision, wherein one part of the correcting lens corrects for pre-existing myopia while another part has less negative power than the focal power of the lens to be able to produce simultaneous myopic defocus and thereby aid in the retardation of myopia progression. U.S. Pat. No. 6,045,578 (Collins and Wildsoet) proposes the addition of positive spherical aberration at the fovea to provide a stimulus that will reduce and/or control myopia progression. U.S. Pat. No. 7,401,922 (Legerton et al) proposes a method and system of treating myopia progression in myopic patients by inducing certain aberration profiles that have positive spherical aberration to produce a wavefront disposed in front of the retina. U.S. Pat. No. 7,803,153, B2 (Thorn et al) proposes a method of preventing myopia progression through identification and correction of all optical aberrations, including higher order aberrations.
In addition to proposed optical strategies to counter the development of refractive error and its progression, in particular myopia, there has also been interest in strategies that involve non-optical intervention like pharmacological substances, such as atropine or pirenzipine.
Another condition of the eye is presbyopia, in which the eye's ability to accommodate is reduced or the eye has lost its ability to accommodate. Presbyopia may be experienced in combination with myopia, hyperopia, astigmatism and higher order aberrations. Many different methods, devices and lenses to address presbyopia have been proposed, including in the form of bifocal, multifocal or progressive addition lenses/devices, which simultaneously provide two or more foci to the eye. Three common types of lenses used for presbyopia are centre-near, centre-distance aspheric multifocals and concentric (ring-type) bifocals alternating between distance and near powers.
In addition, on occasion it is necessary to remove the crystalline lens of an eye, for example if the person is suffering from cataracts. The removed natural crystalline lens may be replaced by an intraocular lens. Accommodating intraocular lenses allow the eye to control the refractive power of the lens, for example through haptics extending from the lens to the ciliary body.
Disclosed herein are various lenses, devices and methods for providing an aberration profile for an eye. Characteristics of aberration profiles and methodologies for identifying aberration profiles are described for myopic eyes, hyperopic eyes and presbyopic eyes. In addition lenses, devices and methods for an eye with astigmatism are disclosed.
In one embodiment, a lens for an eye has an optical axis and an aberration profile about its optical axis, the aberration profile having a focal distance and including at least one of a primary spherical aberration component (C(4,0)) and a secondary spherical aberration component (C(6,0)). The aberration profile provides a retinal image quality (RIQ) with a through focus slope that degrades in a direction of eye growth; and a RIQ of at least 0.30. The RIQ is Visual Strehl Ratio measured along the optical axis for at least one pupil diameter in the range 3 mm to 6 mm, over a spatial frequency range of 0 to 30 cycles/degree inclusive and at a wavelength selected from within the range 540 nm to 590 nm inclusive. In other embodiments the RIQ measure may be different.
In another embodiment, a lens includes an optical axis and an aberration profile about the optical axis that provides a focal distance for a C(2,0) Zernike coefficient term; a peak Visual Strehl Ratio (‘first Visual Strehl Ratio’) within a through focus range, and a Visual Strehl Ratio that remains at or above a second Visual Strehl Ratio over the through focus range that includes said focal distance, wherein the Visual Strehl Ratio is measured for at least one pupil diameter in the range 3 mm to 5 mm, over a spatial frequency range of 0 to 30 cycles/degree inclusive, at a wavelength selected from within the range 540 nm to 590 nm inclusive, and wherein the first Visual Strehl Ratio is at least 0.35, the second Visual Strehl Ratio is at least 0.10 and the through focus range is at least 1.8 Diopters.
In one embodiment, a method for a presbyopic eye includes identifying a wavefront aberration profile for the eye, the wavefront aberration profile including at least one spherical aberration term. The prescription focal distance of the aberration profile is determined taking into account said spherical aberration and wherein the prescription focal distance is at least +0.25 D relative to a focal distance for a C(2,0) Zernike coefficient term of the wavefront aberration profile. The method includes producing a device, lens or corneal profile for the eye to affect said wavefront aberration profile.
In one embodiment, a method for a myopic eye includes identifying a wavefront aberration profile for the eye and applying or prescribing the aberration profile. The wavefront aberration profile includes at least one spherical aberration term, wherein the prescription focal distance of the aberration profile is determined taking into account said spherical aberration and wherein the prescription focal distance is at least +0.10 D relative to a focal distance for a C(2,0) Zernike coefficient term of the wavefront aberration profile. The wavefront aberration profile also provides a degrading retinal image quality in the direction posterior to the retina.
A method for a hyperopic eye, the method comprising identifying a wavefront aberration profile for the eye and applying or prescribing the aberration profile. The wavefront aberration profile includes at least one spherical aberration term, wherein the prescription focal distance of the wavefront aberration profile is determined taking into account said spherical aberration. At the prescription focal distance the wavefront aberration profile provides an improving retinal image quality in the direction posterior to the retina.
In some embodiments a computational device includes an input to receive first combination of aberrations, one or more processors to compute a second combination of aberrations for one or more optical surfaces, and an output to output the second combination of aberrations, wherein the computed second combination of aberrations provides in combination with the first combination of aberrations a total combination of HOA as described above.
Further embodiments will become apparent from the following description, given by way of example and with reference to the accompanying drawings.
The optical performance of the human eye is limited by a number of factors. Major factors include monochromatic and polychromatic optical wavefront aberrations, in addition to the retinal sampling which imposes a Nyquist limit on spatial vision. Minor factors include the Stiles-Crawford Effect and scattering. A quantitative measure of retinal image quality (RIQ) can be defined once all factors affecting image quality are quantified. A measure of RIQ may use a combination of factors that is a subset of all the factors that influence image quality.
1. Retinal Image Quality (RIQ)
With use of a wavefront aberrometer, such as a Hartmann-Shack instrument, the optical characteristics of a candidate eye can be measured so as to identify a measure of retinal image quality (RIQ). Several measures of RIQ are described below.
Once the wavefront aberration of the candidate eye is availed, the image quality at the retina of the eye can be determined by computing the simple Strehl ratio, as described in the Equation 1. The Strehl ratio can be computed in both spatial domain (i.e. using Point spread function) and in Fourier domain (i.e. using Optical transfer function as shown below in equation 1). The Strehl ratio measure is always bound between 0 and 1, where 1 is associated with best image quality.
U.S. Pat. No. 7,077,522 B2 (Williams), which is hereby incorporated by reference herein in its entirety, describes a vision metric called the sharpness metric, by taking into account both the wavefront aberration and the retinal response to the image. This metric can be computed by convolving a point spread function with a neural quality function. Further, U.S. Pat. No. 7,357,509 B2 (Williams et al 2008) describes several other metrics to gauge optical performance of the human eye.
One such RIQ measure is the Visual Strehl Ratio, which calculated in the frequency domain. The Visual Strehl Ratio in the frequency domain is described by Equation 2 and is always bound between 0 and 1, where 1 is associated with best image quality at the retina.
This metric only considers monochromatic aberrations.
The RIQ measure of monochromatic Visual Strehl Ratio shows high correlation with objective and subjective visual acuity (e.g. Thibos et al. Journal of Vision 2004). This measure has been predominantly been used to describe RIQ in the remainder of this specification. However, other measures described herein and alternatives thereto may be used in the design of optical devices, lenses and methods.
The Visual Strehl Ratio defined by Williams, discussed above, is limited to monochromatic light. To accommodate for polychromatic light, a metric called the polychromatic retinal image quality (polychromatic RIQ) is defined that includes chromatic aberrations weighed with spectral sensitivities for selected wavelengths. The polychromatic RIQ measure is defined in Equation 3.
The Visual Strehl Ratio or monochromatic RIQ discussed above in sub-section B is limited to on-axis vision. As used herein, unless the context clearly requires otherwise, ‘on-axis’ is a reference to any one of the optical, visual or papillary axis. To accommodate for wide angle view (i.e. peripheral visual field), a metric called the global retinal image quality (GRIQ) is defined that includes range of visual field eccentricities. A monochromatic GRIQ measure is defined in Equation 4.
One other form of RIQ metric that accommodates for polychromatic light and wide angle view (i.e. peripheral visual field), a metric is called the polychromatic global retinal image quality (GRIQ) is defined that includes chromatic aberrations weighed with spectral sensitivities for selected wavelengths and range of visual field eccentricities. A polychromatic GRIQ measure is defined in Equation 5.
In Equations 1 to 5:
Wdiff (ρ, θ) denotes wavefront phase of the diffraction limited case;
ρ and θ are normalised polar coordinates, where p represents the radial coordinate and
θ represents the angular coordinate or the azimuth;
λ denotes wavelength;
α denotes field angle;
φ denotes the meridian angle;
S(λ) denotes spectral sensitivity.
The wavefront phase, for example, can be written as a function set of standard Zernike polynomials up to a desired order, as described below,
Where, αi denotes the ith coefficient of Zernike polynomial
These polynomials can be represented in the Optical Society of America format or Malacara format or other available Zernike polynomial expansion formats. Apart from the Zernike method of constructing the wavefront phase, any other non-Zernike method of wavefront phase construction can also be adopted i.e. Fourier expansion, Taylor expansion, etc.
All the factors included in the above RIQ variants include wavefront aberration, chromaticity and spectral sensitivity, Stiles-Crawford Effect of the first kind, and optical/visual performance in the peripheral retina. Another factor that can be included is the amount of time spent at various accommodative states on an average day (the daily amount of near work), also known as the myopic impetus exposure time, T (A). This provides the following GRIQ variant:
As mentioned above, other measures of RIQ proposed can also be used in the design of devices, lenses and methods. One example of an alternative RIQ measure is simple modulation transfer function (MTF). Referring to Equation 2, a polychromatic MTF is formed by computing the modulus of real part of the optical transfer function and in addition excluding the step of convolution with the CSF function. A monochromatic MTF is formed if S(λ) is also removed from Equation 2.
2. Through Focus RIQ
RIQ may also be considered anterior and/or posterior to the retina. The RIQ anterior and/or posterior to the retina is called ‘through focus RIQ’ herein. Similarly, RIQ at and/or around the retina may also be considered over a range of focal lengths (i.e. when the eye accommodates, which causes refractive characteristics of the eye in addition to the focal length to change).
Embodiments consider not only RIQ at the retina, but also the change in through focus RIQ. This is in contrast to an approach that may, for example, consider only the RIQ at the retina and/or an integral or summation of RIQ measures at or around the retina. For example, embodiments of the lenses, devices and methods described herein effect, or are designed to effect for an eye with particular refractive characteristics, a change in or control over the extent or rate of change in RIQ in the directions anterior to the retina (i.e. the direction from the retina towards the cornea) and/or posterior to the retina.
Embodiments also effect, or are designed to effect a change in or control over the variation in RIQ with focal distance. For example several candidate lens designs may be identified through effecting a change in the retinal image quality in the direction posterior to the retina and then a single design or subset of designs may be identified taking account of variation in RIQ with change in focal length.
In other embodiments the process described above is reversed. In particular, a set of designs is selected based on changes in RIQ at the retina with focal distance. Selection within the set is then made with reference to the through focus RIQ.
In still other embodiments a single evaluation process is conducted that combines consideration of through focus RIQ and changes of RIQ at the retina with a said focal distance. For example, an average measure of RIQ with changes in focal distance may be used to identify a design. The average measure may give more weight to particular focal distances (e.g. distance vision, intermediate vision and near vision and therefore may be weighted differently),
In various embodiments, through focus and/or changes of RIQ at the retina with focal distance are considered: i) on-axis, ii) integrated around on-axis, for example in an area corresponding to or approximating a pupil size, with or without consideration of the Stiles-Crawford effect, iii) off-axis (where off-axis means a location, set of locations or integral of locations on the retina outside the fovea, which may be where light at field angles more than about 10 degrees is focused), and/or iv) for a combination of i) to iii).
While the description herein refers predominantly to quantitative measures of RIQ, qualitative measures may be used in the design process of an aberration profile instead or in addition to the quantitative measures. For example, the Visual Strehl Ratio at a particular through focus location is computed based on the point spread function. As can be seen from the example images referred to in the following section, the point spread function can be visually evaluated. This provides for a method of qualitatively evaluating through focus.
3. Aberrations Affecting Image Quality at the Retina and Through Focus RIQ
The influence of lower order aberrations on retinal image quality and through focus RIQ is well understood. The use of corrective lower order aberrations represents a traditional method of refractive error correction for an eye. Accordingly, the identification of an aberration profile consisting of lower order aberrations to correct for defocus and astigmatism will not be described herein in detail.
The influence of higher order aberrations (HOA) on image quality can be appreciated from the through-focus two-dimensional point spread functions 300 illustrated in
The point spread functions without any higher order aberrations 302 (in the illustrated example images at the retina in an eye with myopia or hyperopia alone), with vertical coma 306 alone, and with horizontal trefoil 308 alone, remain symmetrical with positive and negative defocus. With positive and negative primary spherical aberrations, either alone 304 or in combination 310 with coma and/or trefoil, the through-focus in the point spread function is asymmetrical for positive and negative defocus. With certain HOA positive and negative defocus has unequal effects on the image quality. It can be seen that these unequal effects are more pronounced for spherical aberrations. The HOA that exhibit asymmetrical effects on RIQ, visual acuity and/or contrast sensitivity have particular application to the lenses, devices and methods disclosed herein.
The interactions occurring between HOA and defocus influence the through-focus RIQ. Some HOA interact favourably with defocus to improve RIQ, while others interact unfavourably to cause RIQ degradation. The most commonly measured higher order ocular aberrations include spherical aberration, coma and trefoil. Apart from these, the HOA profiles obtained with some multifocal optical designs precipitate considerable magnitudes of wavefront aberrations, often expressed up to the 10th order in Zernike polynomial representation.
Generally, in the Zernike pyramid, the terms closer to the centre are often more influential when gauged in terms of the resultant optical effects than those at the edge/corner. This may be because the terms farther away from the centre have a relatively large planar area on the wavefront compared to those whose angular frequency is closer to zero. Accordingly, Zernike terms that have the highest potential to interact with defocus are, for example, the terms with even radial order having zero angular frequency component, i.e. the fourth, sixth, eighth, and tenth order Zernike coefficients, representing primary, secondary, tertiary and quaternary, spherical aberrations.
The foregoing description of aberrations identifies some of the aberrations that affect retinal RIQ and through focus RIQ. The description is not, nor is it intended to be, an exhaustive description of all aberrations that affect retinal RIQ and through focus RIQ. In various embodiments additional aberrations that affect the retinal RIQ and/or through focus RIQ may be considered, the relevant aberrations being identified having regard to the current refractive state of the ocular system (meaning the eye together with any lenses or optical devices that affect the wavefront received by the retina) and a target retinal RIQ/through focus RIQ.
4. Optimising RIQ
When designing or selecting a required change in refractive state of an eye a measure of RIQ and through focus RIQ is required. In particular, finding a magnitude and sign of defocus of the relevant aberrations that produces an acceptable RIQ and through focus RIQ is required. The search is for the best or at least an acceptable combination of RIQ and through focus RIQ. In some embodiments described herein, a merit function S=1/RIQ is used for this purpose.
Identifying aberration coefficients that optimise RIQ at the retina may be achieved by finding a minimum value of the function S. Considering this in combination with through focus RIQ adds complexity to the optimisation process. Various methods can be used to address this complexity.
One example is to use a non-linear, unconstrained optimization routine, over the chosen group of Zernike SA coefficients as variables. A random element, either automatic or through human intervention may be incorporated to shift to different locations so as to find alternative local minima of the function S. The criteria by which the optimisation routine evaluates performance may be a combination of retinal RIQ and keeping the through focus RIQ within predefined bounds of the retinal RIQ. The bounds may be defined in various ways, for example as a range about the value for retinal RIQ. The range may be fixed (e.g. plus or minus 0.15 for Visual Strehl ratio or GRIQ or similar measure), or may vary (e.g. be within a defined rate of change with increasing distance from the retina). As explained in more detail herein below, the objective range for through focus RIQ may change depending on whether the objective is to provide a sloped through focus RIQ so as to provide stimulus to inhibit or encourage eye growth under an optical feedback explanation of emmetropisation, or to provide a flat through focus RIQ.
Another approach is to limit the number of possible aberration profiles. One way of limiting the possible aberration values is to specify that the Zernike coefficients can only have values corresponding to increments of 0.05 μm focus, or another increment interval. The interval can be selected having regard to the available computational resources. By limiting the number of allowable coefficient values it is possible to simulate the performance of all aberration profiles formed by the combinations of Zernike coefficients, following which those with the best or acceptable on-axis RIQ and through focus RIQ can be identified. The results of this process may be used to constrain more fine-tuned analysis, for example by returning to an optimisation routine with coefficient values within a small range around an identified candidate combination.
5. Controlling Stimulus for Refractive Error Progression by Optical Feedback
In some embodiments a lens, device or method that incorporates an aberration profile to provide a particular on-axis RIQ and through focus RIQ is applied to an eye with progressing myopia or an eye identified as at risk of developing myopia. A person may be identified as being at risk of developing myopia based on a number of indicators, including whether their parents experienced myopia/progressing myopia, their ethnicity, lifestyle factors or otherwise. A person may be identified as being at risk of developing myopia if their eye(s) have an RIQ that improves in the direction of eye growth (when eye growth is not required), either with or without any correction that is currently being used (e.g. with or without a current prescription of lens). The use of improving RIQ in the direction of eye growth may be used alone or in conjunction with other indicators, for example the other indicators listed above.
Under an optical feedback mechanism explanation of emmetropisation based on RIQ, the eye is stimulated to grow to the position where the merit function S is minimised. Under this explanation of emmetropisation, for human eyes, if the location of the minimum of the function S (which may be a local minimum) is posterior to the retina or if through focus RIQ improves posterior to the retina, the eye will be stimulated to grow longer and if this location is on or anterior to the retina, then the eye will remain at the same length. The lenses, devices and methods disclosed herein may be applied to provide stimulus under this optical feedback mechanism explanation of emmetropisation. Embodiments for addressing eye growth under the optical feedback explanation of emmetropisation (e.g. to address myopia progression or to seek to stimulate eye growth to correct hyperopia) use aberrations to affect one or both of the location of the minima of the function S relative to the retina and the gradient of the function S through the retina.
The following description describes how combinations of selected HOA can affect a change in a measure of through focus RIQ. Each of these aberrations can readily be incorporated into a lens, optical device or used in a method of changing the aberration profile of light received by the retina. This provides a mechanism by which a lens, optical device or method of changing the refractive state of an eye (e.g. refractive surgery) can be designed or selected to obtain a target through focus RIQ for an eye, or at least change the refractive state of the eye to closer to a target through focus RIQ. As described in more detail below, achieving a target through focus RIQ is considered together with achieving or getting closer to a target on-axis RIQ at the retina for particular focal length, which is typically distance vision (objects at infinity or practically for human eyes, greater than 3 meters to about 6 meters), but which may be another selected focal length, for example intermediate vision (e.g. about 0.75-2 meters) or near vision (e.g. about 0.35 to 0.60 meters).
For the examples described below the RIQ was evaluated using the Visual Strehl Ratio shown in Equation 2.
The interactions between primary spherical aberration, coma and trefoil and their affect on eye growth can be described using a wavefront phase function defined using defocus, primary spherical aberration (PSA), coma and trefoil terms of a standard Zernike expansion.
The pupil size was fixed at 4 mm and the calculations were performed at 589 nm wavelength. For the purposes of evaluating affects of aberration profiles on ocular growth, it was assumed that a location of a minimum of the above described function S posterior to the retina provides a stimulus to grow to that location and that there will not be stimulus for eye growth if the minimum of the function S is on or in front of the retina. In other words, it is assumed that the image formed on the retina provides a stimulus to grow to minimise the function S. The range of values of PSA, horizontal and vertical coma, and horizontal and vertical trefoil that were used in the simulations are:
PSA=(−0.30, −0.15, 0.00, 0.15, 0.30) μm
Horizontal Coma=(−0.30, −0.15, 0.00, 0.15, 0.30) μm
Vertical Coma=(−0.30, −0.15, 0.00, 0.15, 0.30) μm
Horizontal Trefoil=(−0.30, −0.15, 0.00, 0.15, 0.30) μm and
Vertical Trefoil=(−0.30, −0.15, 0.00, 0.15, 0.30) μm.
With a total of 3125 combinations tested, overall it was observed that spherical aberration primarily governed the direction of improving RIQ.
The above described stimulus for eye growth may accordingly be removed by controlling the refractive state of an eye to be within any of the white areas in
Although trefoil and coma in the range of −0.30 to 0.30 μm over a 4 mm pupil do not appear to have a significant impact on the direction of growth (the maximum progression effect is only −0.1D), positive PSA seems to accelerate growth while negative PSA inhibits growth. The PSA therefore appears to have the dominant effect. Accordingly, at least for an eye with positive PSA and optionally one of coma and trefoil, adding negative PSA will inhibit eye growth under the optical feedback explanation of emmetropisation. It follows that providing negative PSA to an eye, or at least removing positive PSA may remove the stimulus for eye growth. Any coma and trefoil in the eye may be left unchanged or optionally partially or fully corrected (preferably within the range of −0.30 to 0.30 μm).
To illustrate the interactions between primary spherical aberration and astigmatism, a wavefront phase function was defined using these aberrations (including both horizontal/vertical and oblique components) and defocus.
A stimulus for eye growth may accordingly be removed by controlling the refractive state of an eye to be within any of the white areas in
From
For unaided or single-vision spectacle corrected eyes a fourth order Zernike expansion is generally sufficient to describe the wavefront at the exit pupil. However, this is not necessarily the case when contact lenses are used for correction, especially with multifocal contact lenses (both aspheric and concentric), substantial amounts of fifth order and higher HOA may be imposed. Multifocal contact lenses may for example be described using up to about the tenth or twentieth order of Zernike polynomials. In such cases the magnitudes and signs of the higher order spherical aberrations start to play a significant role (in addition to PSA).
To illustrate the interactions between primary, secondary, tertiary and quaternary spherical aberrations of a standard Zernike expansion, a wavefront phase was defined using these terms and defocus. Several combinations of HOA as predicted from modelled data with such multifocal contact lenses were used. Selective sets of these HOA that demonstrate interactions to produce peak RIQ were obtained via dedicated non-linear optimization routines. All the calculations were performed over a 4 mm pupil, and at 589 nm wavelength. It was observed that at least the first three modes of spherical aberration of the inherent eye played a significant role in governing the direction of stimulus for eye growth and in some cases higher modes of spherical aberration also played a significant role.
The results described below relate to secondary spherical aberration (SSA), tertiary spherical aberration (TSA) and quaternary spherical aberration (QSA), but spherical aberrations with higher orders may also be used in embodiments of the lenses, devices and methods described herein. For all four types of spherical aberrations, a range from −0.30 to 0.30 μm was used to investigate the effects of the combinations of HOA. These ranges for these types of aberrations do not necessarily accord with normative distributions of aberrations associated with eyes because the occurrence of these higher order aberrations are not necessarily associated with the eyes but with the optical devices (such as multifocal contact lenses) alone or in combination with the eyes. Furthermore, the range from −0.30 to 0.30 μm is merely used to illustrate the effects, but when determining combinations of HOA to provide an aberration profile in a lens or optical device, or to be effected by surgical procedures, larger or smaller ranges may be used.
The majority of the black filled circles 1304 are in the region governed by negative SSA, with a few exceptions. Further, combinations in which PSA and TSA have the same sign coupled with negative SSA seem to provide a protective effect against myopia progression. The combinations of PSA, SSA, TSA and QSA that have a protective effect against myopia progression under the optical feedback explanation of emmetropisation (which include the black areas shown in
The majority of the white circles 1302 are in the region governed by positive SSA, with a few exceptions. Further, combinations in which the PSA and TSA have the same sign coupled with positive SSA may provide a treatment effect for hyperopia. The combinations of PSA, SSA, TSA and QSA that have a treatment effect against hyperopia under the optical feedback explanation of emmetropisation (including the white areas shown in
Accordingly, when designing a lens, optical device or method of altering the eye, the aberrations may be selected to provide a combination of the aforementioned aberrations that provide for either a protective effect against eye growth, or which encourage eye growth. The combination of aberrations may be applied in combination with the required correction of any myopic defocus or hyperopic defocus.
From the foregoing description, it is apparent that the spherical aberration terms, including the primary, secondary, tertiary and quaternary SA terms influence RIQ and through focus RIQ. In addition, it has been found that much higher orders of spherical aberration also influence RIQ and through focus RIQ. Accordingly in various embodiments different combinations of spherical aberration are used, including embodiments using any combination of two or more spherical aberration terms that provide a required or acceptable through focus RIQ profile, together with a required or acceptable RIQ at a particular focal length (e.g. distance vision).
6. The Instantaneous Gradient of the Image Quality
The foregoing description of stimulus for eye growth under the optical feedback mechanism explanation of emmetropisation focused on the location of the peak RIQ. Another approach is to consider the slope of through-focus RIQ at the retina. In some embodiments, methods and devices control or utilise this gradient of the image quality metric. The gradient may be considered for any measure of RIQ.
In the following description it is assumed that a positive measure of the gradient of the through-focus RIQ (increasing RIQ posterior to the retina) provides a stimulus for the development and progression of myopia, while a negative measure of the same retards or halts myopia progression.
From the results described above that indicate the effects of HOA on image quality and the resulting progression of myopia, it is possible to determine the relevant HOA combinations that can be used in lenses, optical devices, or effected using optical surgery, which, where relevant in combination with the eye's aberrations, will result in the HOA combinations that inhibit or retard eye growth for the treatment of myopia progression. In order to slow down eye growth in myopia, compensating optical devices or surgical procedures can be used that, in combination with the optics of the eye, will result in a combination of HOA that results in a negative gradient of through-focus retinal image quality, as shown in example 1404 (
If an aberration profile has a varying RIQ across a through focus range, then the slope of through focus RIQ at a particular focal length can be changed by selecting a suitable defocus term C(2,0) with the considered RIQ profile. For example, if the slope is positive at a first level of through focus and negative at a second level of through focus, the slope at the retina of a recipient eye can be selected by selectively introducing defocus at either the first or second level. Examples of aberration profiles that have varying RIQ slopes at different levels of defocus are provided below in relation to embodiments of aberration profiles for application to presbyopia. Many of the embodiments described for presbyopia may be applied to provide a stimulus to retard or encourage eye growth under the optical feedback explanation of emmetropisation described above. Typically, younger people have progressing myopia and as such they will not be experiencing presbyopia. Accordingly, the aberration profile selected may place less weight on achieving high RIQ over a large through focus range and more weight on achieving the highest RIQ at the retina for distance vision in combination with providing a negative slope RIQ profile through the retina (i.e. decreasing RIQ in the direction of eye growth). For the young hypermetropes, again, the selected aberration profile may place less weight on achieving high RIQ over a large through focus range and more weight on achieving the highest RIQ at the retina for distance in combination with provision of a positive slope of RIQ profile behind the retina (in the direction of eye growth).
In addition, the slope across a range of field angles can be considered and/or variations in the RIQ for a range of pupil sizes. For example, an aberration profile may be selected that provides an average, mode or substantially uniform slope across a range of field angles, such as 10, 20, 30 or 40 degrees that either inhibits or encourages eye growth (and/or cancel existing aberrations in the eye that encourage or inhibit eye growth respectively). The average slope across the range of pupil sizes or at the mode pupil size may also be considered. Alternatively, the design may be selected that has either a positive or negative slope of through focus RIQ for all field angles within a range and/or for all pupil sizes with a range.
7. Aberration Design or Selection Process
In some embodiments determining the aberration profile required in a lens, optical device or resulting from a procedure, includes first identifying the HOA present in the eye. Measurements may be taken, for example, using wavefront eye exams that use aberrometry such as with a Shack-Hartmann aberrometer. The eye's existing HOA may then be taken into account. In addition, any HOA effects inherent in the lenses or optical devices may also be taken into account.
When the requirement is for a lens that provides stimulus for eye growth or to retard eye growth, these existing HOA are then compared to HOA combinations that inhibit or retard myopia progression (for example as discussed above with reference to
Alternatively, the eye's existing aberrations may be disregarded and an aberration profile that provides the required through focus RIQ slope may be provided for the eye by a lens, preferably a removable lens so that different aberration profiles may be trialled if required. The aberration profile resulting from the combination of the aberration profile of the lens and the eye may then be measured to determine if the RIQ characteristics are acceptable (for example, provide a particular through focus RIQ slope and acceptable RIQ for distance vision). Alternatively, different lenses may be placed on the eye with measures of objective and/or subjective vision determining which lens to select. Where the lens is selected to provide stimulus inhibiting or encouraging eye growth without regard to the eye's existing aberrations, the selected aberration profile may be one with generally higher values of spherical aberration, so that the sign of the slope is not changed by lower level of HOA in the eye.
In other applications, the goal for the combination of HOA may be different. For example, when considering presbyopia the goal may be a combination of aberrations that provide high RIQ over a large through focus. Where peripheral vision is important, then the objective may include high RIQ over a large range of field angles. Accordingly, in various embodiments the HOAs are utilised to optimise for the goals of a combination of high RIQ at the retina and one or more of a low slope through focus RIQ, a low change in RIQ with pupil diameter and a high RIQ in the peripheral field.
The examples that follow have been selected using the RIQ measure in Equation 2. The initial set of designs for analysis was found by computing this RIQ for all combinations of SA Zernike coefficients up to the 10th order. Each coefficient was constrained to the range −0.3 μm to 0.3 μm and constrained to be a value that is a multiple of 0.025 μm.
An analysis of the initial set of designs included: 1) identifying optimised combinations of Zernike coefficients that provide a high RIQ and a negative slope through focus RIQ about the retina; 2) consideration of the RIQ and through focus RIQ and change in RIQ and through focus RIQ at different pupil sizes; and 3) consideration of the RIQ across the horizontal visual field. The relative weight given to these stages of evaluation may vary for the particular recipient. For the purposes of identifying the following examples, most weight was given to the first criteria.
8. Examples of Optical Designs Addressing the Slope of Through Focus RIQ
Examples of designs for affecting stimulus for eye growth under an optical feedback mechanism are provided herein below. The examples below are rotationally symmetric. However, astigmatic designs and other non-rotationally symmetric designs may be produced. When a deliberate decentration of the symmetric designs is imposed so that the optical axes of the correcting contact lens coincides with a reference axis of the eye say pupillary axis or visual axis, some residual amounts of asymmetric aberrations like coma and trefoil can be induced, these may be compensated by the choice of additional higher order asymmetric terms.
As explained above, the example power profiles shown in
Table 3 lists the defocus and higher order aberrations coefficients up to 20th order, in microns, over a 5 mm pupil diameter for the above described power profiles.
9. Application to Presbyopia
Extending the through focus RIQ may provide particular benefit in the context of presbyopia. The reduced ability of the eye to accommodate may be partially compensated/mitigated by using the extended through focus approach described herein.
In some embodiments the through focus RIQ is extended further by taking a monocular approach. In particular, one eye may have aberrations optimised for distance vision and the other eye optimised for near vision. This optimisation is achieved by selecting different base powers (i.e. effective refractive prescriptions) for the lenses. The extended through focus of each lens allows the base powers to be separated further without sacrificing intermediate vision between the two base powers. Under the monocular approach, selection of an aberration profile may give a higher priority to the consideration of the RIQ and through focus RIQ, and change in RIQ and through focus RIQ at different pupil sizes (which reflect the change in the eye with different accommodation).
Similarly, a lens or optical device may be designed as a bifocal or multifocal lens, with one or both of the parts incorporating aberration profiles as described herein to extend through focus RIQ. A combination of bifocal/multifocal lenses or devices and the monocular approach can increase the range of vision. For example, with reference to bifocal lenses one eye may have far distance vision in the upper quadrants and near vision in the lower quadrants and the other eye may have intermediate vision in the upper quadrants and near vision in the lower quadrants. The two lower quadrants may optionally have different base powers, for example set at 2.00 D and 1.00 D.
When different lenses or different parts of lenses are used together, the base powers may be selected so that the through focus RIQ overlaps. For example, the base powers may be selected so that in combination the Visual Strehl Ratio does not drop below 0.10, 0.20, 0.30, 0.40 or another selected value, between the combined RIQ profiles.
The seven power profiles are: a power profile that may appear in a conventional centre-distance aspheric multifocal lens (indicated by triangles in
The power profiles for each of these are shown in
Table 4 lists the defocus and higher order spherical aberration coefficients up to 20th order, in microns, over a 5 mm pupil diameter, for the three exemplary embodiment power profiles, namely: Iteration B1 (
Table 5 lists out the defocus and higher order spherical aberration coefficients up to 20th order, in microns, over a 5 mm pupil diameter, for the described power profiles, namely, centre-distance aspheric multifocal (
In the aspheric multifocal lenses the spherical aberration coefficients progressively decrease in absolute magnitude with an increase in order. This is in contrast to the power profiles of Iteration B1, Iteration B2 and Iteration B3, which include at least one higher order spherical aberration term with an absolute value coefficient greater than the absolute value of the coefficient for a lower order term. This characteristic is present in many embodiments of power profile described herein.
From
The centre-near aspheric multifocal has a RIQ for distance vision, of about 0.50. The centre-near bifocal falls to an RIQ of about 0.24 at −0.67 Diopters (still better than the centre-distance aspheric multifocal). However, beyond that the centre-near aspheric multifocal has a rapidly decreasing RIQ and at −1.0 Diopters has an RIQ of about 0.08.
Both of the concentric bifocals (centre-distance and -near) have a low RIQ of 0.13 and 0.21 for distance vision. Both of the concentric bifocals maintain their level of RIQ or better over a range of approximately 1.1 Diopters.
Iteration B1, Iteration B2 and Iteration B3 all have at least as good RIQ at distance vision as the centre near bifocal and better RIQ as the eye accommodates. For example Iteration B2 has an RIQ of about 0.53 at −0.40 Diopters, about 0.32 at −0.67 Diopters and about 0.13 at −1.0 Diopters. However, the through focus performance of each of Iteration B1, Iteration B2 and Iteration B3 can be further extended. This extension is achieved by shifting the curves to the left in
For example, all three of these iterations have an RIQ of about 0.40 at +0.55D. Combining the spherical aberration terms with a +0.55D defocus term will shift the RIQ value for distance vision to the value for +0.55 D in
Accordingly, by shifting the distance vision point in a lens with combinations of HOA that extend through focus RIQ performance, then the lenses, devices and methods that provide the combination of HOA can have a substantially improved through focus performance. This is achieved while maintaining at least as good RIQ as a centre near aspheric multifocal and substantially improved RIQ in comparison to a centre distance aspheric multifocal. The amount of defocus plus power added to shift the RIQ curves is a matter of choice, representing a trade-off between distance vision RIQ and near vision RIQ.
Table 6 shows the defocus (leftmost column) and RIQ values for each of the power profiles described above. It also shows the defocus values shifted by +0.55D, applicable when to Iteration B1, Iteration B2 and/or Iteration B3 are modified by this amount.
As described above, Iteration B2 can provide an RIQ of 0.40 or above from distance vision to about an intermediate vergence of about 1.1 Diopters. When appropriate level of defocus is added to the same iteration while correcting the other eye, through-focus RIQ can be extended from 1.1 Diopters to up close, say 2.20D target vergence, i.e. binocularly combined the candidate eye may maintain an RIQ of 0.40 or above from distance test distance to all the way up close to 2.2 Diopters. Using this monocular design approach and assuming the recipient accepts the monocular design, the combined through focus performance is substantially extended.
Referring to the through focus profiles shown in
The power profiles described in relation to Table 7 and Table 8 are examples of combinations of higher order aberrations that provide enhanced through-focus performance on the negative side of the through-focus function. Similarly, using this monocular design approach, the combined through-focus performance can also be substantially extended on the right side of the through-focus function, provided an appropriate level of defocus is added to a selected combination of higher order aberrations.
10. Design for Peripheral Field
In some embodiments, when selecting a combination of HOA to form a power profile, the weight given to peripheral vision may be increased. This may, for example, be applicable when the recipient plays certain sports in which peripheral vision is important.
Each of Iteration A3, Iteration A4 and Iteration A5 produced an on-axis RIQ of about 0.50 across zero to 30 degrees field angle (if horizontal symmetry is assumed, that is 60 degrees in total across both nasal and temporal fields). The RIQ on-axis is also about 0.50, which is lower than some other embodiments where degradation in RIQ below 0.50 with increasing field angle is permitted.
Accordingly, in further embodiments, the RIQ on-axis may be traded-off against RIQ at high field angles. For example, RIQ may be permitted to drop to 0.20 at 30 degrees field angle (but remain at 0.50 or above for 20 degrees field angle and less), to allow a selection of HOA that increases on-axis RIQ above those shown in
11. Selection of Positive and Negative Phase
For any particular recipient of a lens, device or a method disclosed herein, a selection may be made between any two power profiles of opposite phases. In this context, the term ‘opposite phase’ identifies power profiles that have identical magnitudes of specific combination sets of higher order aberrations over a desired pupil, while their signs are opposite to each other.
The lenses of opposite phase described herein may result in the same on-axis peak RIQ. The through focus RIQ performance of such phase profile pairs may be mirror images of each other across the Y-axis (i.e. shifted apart by defocus), as shown in
The interactions between the inherent aberration profiles of the candidate eyes and a selected phase profile may either have a) an improved or b) degraded effect on the objective/subjective optical/visual performance. As the through-focus RIQ is dependent on the inherent aberration profile, a phase profiles selected for instance may be useful to change the slope of through-focus RIQ in the direction that would favour the emmetropisation process for myopic or hyperopic eyes; or alternatively the same phase profile could be used to mitigate the presbyopic symptoms in alternative candidate eyes.
12. Combination Identification and Selection
As described above, it is possible to provide a desirable on-axis RIQ for distance and appropriate through focus RIQ that would enable better visual performance for intermediate and near vergences by choosing an appropriate combination of HOA. This combination of higher order aberrations may contain a correction for the inherent aberration profile of the test candidate. The Appendix A to this specification lists 78 combinations of higher order spherical aberration coefficients that provide both a usefully high RIQ and an option to provide an extended through focus RIQ in the negative direction (left hand side). Also shown in the Appendix A, as a point of comparison, is a combination which does not have any spherical aberration, of any order. The Appendix B shows the through-focus RIQ values for the combinations listed in the Appendix A. All calculations were performed for a pupil size of 4 mm, however the approach can be extended to any other appropriate/desired pupil sizes if required.
The through-focus RIQ measures of the 78 aberration combinations are shown in
From
The spherical aberration terms vary in the combinations, from one (example: combination 77) through to all nine. In other embodiments even higher orders of spherical aberration terms may be added, to create additional combinations.
The combination 77 in the appendix A introduces only primary spherical aberration. Primary spherical aberration was proposed in the U.S. Pat. No. 6,045,578 (Collins and Wildsoet) for progressing myopia. The combination 77 shows that by selecting a particular level of primary spherical aberration, the aberration profile may be beneficially used for a presbyopic eye. In addition, considering the application of myopia, when combination 77 (or any other embodiment including only PSA) is set with a focal length matching the existing myopia, then the on-axis through focus RIQ is substantially neutral, in that the peak RIQ is placed on the retina. Placing the peak RIQ on the retina would accord with a traditional design approach as taught by Collins. In contrast, a stimulus to retard eye growth on-axis under the optical feedback explanation of emmetropisation is achieved if the retina is located on the negative side of the graph shown in
Appendix C to this specification lists another 67 combinations of higher order coefficients that provide both a usefully high RIQ and an option to provide an extended through-focus RIQ in the positive direction (right hand side). Also shown in Appendix C, as a point of comparison, is a combination which does not have any spherical aberration of any order. The Appendix D shows the through-focus RIQ values for the combinations listed in Appendix C. Again, all calculations were performed for a pupil size of 4 mm, however the approach can be extended to any other appropriate/desired pupil sizes, if required.
The through-focus RIQ measures of the 67 aberration combinations are shown in the
From the
13. Spherical Aberration and Astigmatism
In the previous sections iterations B1, B2 and B3 were described for emmetropic presbyopia. When considering the astigmatic presbyopia, two different methods can be adopted. A first method of correction is completed by considering astigmatic refractive error as an equivalent sphere. In this method, the spherical equivalent prescription is deduced by dividing the cylindrical/astigmatic power divided two (S=−C/2). This is a very common approach often considered to address low to moderate amounts of astigmatism, say up to −1.50D. Once the equivalent sphere is availed, the same iterations described herein, say for example B1, B2 or B3 can be used as an effective prescription, once the defocus term is adjusted to suit the spherical equivalent.
A second method considers preparation of a toric prescription for both astigmatism and presbyopia.
14. Implementation
Aberration profiles of the types described herein above may be implemented in a number of lenses, ocular devices and as methods.
For example, contact lenses (hard or soft), corneal onlays, corneal inlays, and lenses for intraocular devices (both anterior and posterior chamber) may all include the combination aberration profiles discussed. Techniques to design lenses and to achieve a power profile are known and will are not described herein in any detail.
The aberration profiles can be applied to spectacle lenses. However, because the aberration profiles require alignment of the eye with the centre of the optics providing the aberration profile, then benefit may only be apparent for one particular direction of gaze. Recently electro-active lenses have been proposed that can track the direction of gaze and change the refractive properties of the lenses in response. Using electro-active lenses the aberration profile can move with the eye, which may increase the utility of the disclosed aberration profiles for spectacle lenses.
The aberration profile may be provided on a lens of an intraocular lens. In some embodiments the intraocular lens may include haptics that provide for accommodation. In other embodiments the lens may have a fixed focal length. The aberration profile may be provided on a supplementary endo-capsular lens.
The disclosed aberration profiles may be provided to an eye through computer-assisted surgery. For example refractive surgery or corneal ablation may be used to form a selected aberration profile. The power profile or required change in corneal shape is determined and input to the laser system (LASIK or LASEK) for application to the eye of the patient.
Where the aberration profiles are to be included in a lens, then the aberration profile may first be translated into a lens thickness profile for input to computer assisted manufacturing. Taking for example, the lens power profile D1 shown in
The aberration profile may be selected and identified as a custom lens for an individual. The process for design of the aberration profile includes measuring the wavefront aberration of the eye and designing an aberration profile to achieve a through focus RIQ profile described herein. The design process includes identifying the spherical aberration in the natural eye only and designing an aberration profile for the lens, device or method that, in combination with the spherical aberration of the eye provides a required RIQ profile. As described herein above, the required RIQ profile may differ depending on the application of the lens—as different requirements may apply between a person with progressing myopia and a person with presbyopia. In some embodiments other aberrations in the eye, for example astigmatism, coma or trefoil are ignored. In other embodiments, these are taken into account. For example, as described above, the presence of astigmatism affects the combinations of aberrations that provide a through focus RIQ that inhibits eye growth under the optical feedback explanation of emmetropisation. In other embodiments these aberrations are incorporated into the design. For example, when producing a lens design, a base lens may be produced that corrects for any defocus and corrects one or more of astigmatism, coma and trefoil. On top of this base profile is provided a spherical aberration profile designed to achieve (in the sense of using as an objective design) the profiles described herein. The spherical aberration profile may be selected using a trial and error approach, for example by identifying a candidate profile, computing the through focus RIQ and evaluating whether the through focus RIQ has an acceptable profile.
In another approach aberration profiles may be designed for population averages. One approach for designing population average lenses is to normalise the design for pupil size.
The description of the aberration profiles for lenses, devices and methods has been provided by way of mathematical explanation. This allows for precision in describing the aberration profiles. However, lenses, devices and methods will not have such precision. For example tolerances and inaccuracies arising during manufacture will result in variations of the lens profile. The approximate power profile of a lens can be measured using a wavefront aberrometer. From this an approximate measure of through focus RIQ, for example Visual Strehl Ratio, can be determined.
It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
15. Appendix A—Example Combinations of Spherical Aberration
16. Appendix B—Through Focus RIQ for Combinations of Spherical Aberration in Appendix A
17. Appendix C—Example Combinations of Spherical Aberration
18. Appendix D: Through Focus RIQ for Combinations of Spherical Aberration in Appendix C
Number | Date | Country | Kind |
---|---|---|---|
2012901382 | Apr 2012 | AU | national |
2012904541 | Oct 2012 | AU | national |
This application is a continuation of U.S. patent application Ser. No. 16/226,263, filed Dec. 19, 2018, which is a continuation of U.S. patent application Ser. No. 15/399,445, filed Jan. 5, 2017, now U.S. Pat. No. 10,209,535 issued Feb. 19, 2019, which is a continuation of U.S. application Ser. No. 14/565,062, filed Dec. 9, 2014, now U.S. Pat. No. 9,575,334 issued Feb. 21, 2017, which is a continuation of U.S. application Ser. No. 13/857,613, filed Apr. 5, 2013, now U.S. Pat. No. 9,195,074, issued Nov. 24, 2015, which claims priority to Australian Provisional Application No. 2012/901382, entitled, “Devices and Methods for Refractive Error Control” filed on Apr. 5, 2012, and Australian Provisional Application No. 2012/904541 entitled “Lenses, Devices and Methods for Ocular Refractive Error”, filed on Oct. 17, 2012. Each of these applications are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4082432 | Kirschner | Apr 1978 | A |
5260727 | Oksman et al. | Nov 1993 | A |
5422687 | Tanaka et al. | Jun 1995 | A |
5530491 | Baude et al. | Jun 1996 | A |
5662706 | Legerton et al. | Sep 1997 | A |
5682223 | Menezes et al. | Oct 1997 | A |
5684560 | Roffman et al. | Nov 1997 | A |
5699141 | Monteil et al. | Dec 1997 | A |
5715031 | Roffman et al. | Feb 1998 | A |
5742439 | Schuster | Apr 1998 | A |
5748371 | Cathey et al. | May 1998 | A |
5757458 | Miller et al. | May 1998 | A |
5771088 | Perrott | Jun 1998 | A |
5777719 | Williams | Jul 1998 | A |
5796462 | Roffman et al. | Aug 1998 | A |
5805260 | Roffman et al. | Sep 1998 | A |
5815239 | Chapman et al. | Sep 1998 | A |
5822091 | Baker et al. | Oct 1998 | A |
5835192 | Roffman et al. | Nov 1998 | A |
5847802 | Menezes et al. | Dec 1998 | A |
5864378 | Portney et al. | Jan 1999 | A |
5888122 | Gupta et al. | Mar 1999 | A |
5912719 | Baude et al. | Jun 1999 | A |
5929969 | Roffman et al. | Jul 1999 | A |
RE36352 | Swanson et al. | Oct 1999 | E |
5965330 | Evans et al. | Oct 1999 | A |
5971542 | Volker et al. | Oct 1999 | A |
5980040 | Xu et al. | Nov 1999 | A |
5982543 | Fiala et al. | Nov 1999 | A |
6045578 | Collins et al. | Apr 2000 | A |
6046867 | Rana et al. | Apr 2000 | A |
6082856 | Dunn et al. | Jul 2000 | A |
6086203 | Blum et al. | Jul 2000 | A |
6089711 | Blankenbecler et al. | Jul 2000 | A |
6102946 | Nigam | Aug 2000 | A |
6116735 | Wada et al. | Sep 2000 | A |
6120148 | Fiala et al. | Sep 2000 | A |
6123422 | Menezes et al. | Sep 2000 | A |
6142625 | Sawano et al. | Nov 2000 | A |
6145987 | Baude et al. | Nov 2000 | A |
6149271 | Menezes et al. | Nov 2000 | A |
6179420 | Roffman et al. | Jan 2001 | B1 |
6199982 | Oyama et al. | Mar 2001 | B1 |
6199984 | Menezes | Mar 2001 | B1 |
6199986 | Williams et al. | Mar 2001 | B1 |
6221105 | Portney | Apr 2001 | B1 |
6244708 | Chapman et al. | Jun 2001 | B1 |
6244709 | Vayntraub et al. | Jun 2001 | B1 |
6246516 | Ulrich | Jun 2001 | B1 |
6299311 | Williams et al. | Oct 2001 | B1 |
6318859 | Baudart et al. | Nov 2001 | B1 |
6329989 | Qi et al. | Dec 2001 | B1 |
6338559 | Williams et al. | Jan 2002 | B1 |
6359692 | Groot | Mar 2002 | B1 |
6412947 | Yanari | Jul 2002 | B2 |
6428574 | Valunin et al. | Aug 2002 | B1 |
6457826 | Lett | Oct 2002 | B1 |
6474814 | Griffin | Nov 2002 | B1 |
6511180 | Guirao et al. | Jan 2003 | B2 |
6520638 | Roffman et al. | Feb 2003 | B1 |
6533416 | Fermigier et al. | Mar 2003 | B1 |
6536898 | Cathey, Jr. | Mar 2003 | B1 |
6537317 | Steinert et al. | Mar 2003 | B1 |
6547391 | Ross et al. | Apr 2003 | B2 |
6547822 | Lang | Apr 2003 | B1 |
6554425 | Roffman et al. | Apr 2003 | B1 |
6554859 | Lang et al. | Apr 2003 | B1 |
6575574 | Dellavecchia et al. | Jun 2003 | B2 |
6576012 | Lang | Jun 2003 | B2 |
6582076 | Roffman et al. | Jun 2003 | B1 |
6596025 | Portney | Jul 2003 | B2 |
6607274 | Stantz et al. | Aug 2003 | B2 |
6609793 | Norrby et al. | Aug 2003 | B2 |
6634751 | Turner et al. | Oct 2003 | B2 |
6648473 | Dellavecchia et al. | Nov 2003 | B2 |
6660035 | Lang et al. | Dec 2003 | B1 |
6663619 | Odrich et al. | Dec 2003 | B2 |
6673112 | Nigam | Jan 2004 | B2 |
6705729 | Piers et al. | Mar 2004 | B2 |
6709103 | Roffman et al. | Mar 2004 | B1 |
6709105 | Menezes | Mar 2004 | B2 |
6709107 | Jiang et al. | Mar 2004 | B2 |
6719792 | Baikoff | Apr 2004 | B2 |
6733124 | Miyamura et al. | May 2004 | B2 |
6752499 | Aller | Jun 2004 | B2 |
6755524 | Rubinstein et al. | Jun 2004 | B2 |
6764179 | Sakai et al. | Jul 2004 | B2 |
6773107 | Ye et al. | Aug 2004 | B2 |
6786602 | Abitbol | Sep 2004 | B2 |
6790232 | Lang | Sep 2004 | B1 |
6802605 | Cox et al. | Oct 2004 | B2 |
6802606 | Roffman et al. | Oct 2004 | B2 |
6808262 | Chapoy et al. | Oct 2004 | B2 |
6808265 | Cox | Oct 2004 | B2 |
6817714 | Altmann | Nov 2004 | B2 |
6819413 | Neal et al. | Nov 2004 | B2 |
6824563 | Lang | Nov 2004 | B2 |
6827444 | Williams et al. | Dec 2004 | B2 |
6830332 | Piers et al. | Dec 2004 | B2 |
6840619 | Dreher | Jan 2005 | B2 |
6851805 | Blum et al. | Feb 2005 | B2 |
6874886 | Miller et al. | Apr 2005 | B2 |
6874887 | Tyson | Apr 2005 | B2 |
6880933 | Davis et al. | Apr 2005 | B2 |
6882473 | Geier et al. | Apr 2005 | B2 |
6899425 | Roffman et al. | May 2005 | B2 |
6899707 | Scholler et al. | May 2005 | B2 |
6902273 | Suzaki et al. | Jun 2005 | B2 |
6903875 | Achtner | Jun 2005 | B2 |
6923540 | Ye et al. | Aug 2005 | B2 |
6924898 | Deck | Aug 2005 | B2 |
6926710 | Cox et al. | Aug 2005 | B2 |
6929366 | Perel et al. | Aug 2005 | B2 |
6955433 | Wooley et al. | Oct 2005 | B1 |
6976997 | Noolandi et al. | Dec 2005 | B2 |
6986578 | Jones | Jan 2006 | B2 |
7004585 | Lindacher | Feb 2006 | B2 |
7014317 | Gupta et al. | Mar 2006 | B2 |
7018039 | Legerton et al. | Mar 2006 | B2 |
7018040 | Blum et al. | Mar 2006 | B2 |
7025454 | Cathey | Apr 2006 | B2 |
7025455 | Roffman | Apr 2006 | B2 |
7025460 | Smith et al. | Apr 2006 | B2 |
7036931 | Lindacher et al. | May 2006 | B2 |
7040755 | Legerton et al. | May 2006 | B2 |
7040757 | Hall et al. | May 2006 | B2 |
7048759 | Bogaert et al. | May 2006 | B2 |
7052133 | Lindacher et al. | May 2006 | B2 |
7061693 | Zalevsky | Jun 2006 | B2 |
7063422 | Lindacher | Jun 2006 | B2 |
7066628 | Allen | Jun 2006 | B2 |
7073906 | Portney | Jul 2006 | B1 |
7077522 | Williams | Jul 2006 | B2 |
7080906 | Lindacher | Jul 2006 | B2 |
7097301 | Legerton et al. | Aug 2006 | B2 |
7101041 | Lindacher et al. | Sep 2006 | B2 |
7101042 | Perel et al. | Sep 2006 | B2 |
7152975 | Ho et al. | Dec 2006 | B2 |
7172285 | Altmann et al. | Feb 2007 | B1 |
7178918 | Griffin | Feb 2007 | B2 |
7192138 | Lindacher et al. | Mar 2007 | B2 |
7204849 | Portney | Apr 2007 | B2 |
7207675 | Chauveau et al. | Apr 2007 | B1 |
7226166 | Della Vecchia et al. | Jun 2007 | B2 |
7237894 | Lindacher | Jul 2007 | B2 |
7246902 | Meyers | Jul 2007 | B2 |
7246906 | Mihashi et al. | Jul 2007 | B2 |
7249850 | Donetti et al. | Jul 2007 | B2 |
7261412 | Somani et al. | Aug 2007 | B2 |
7264354 | Blum et al. | Sep 2007 | B2 |
7270413 | Hirohara et al. | Sep 2007 | B2 |
7273277 | Sarver | Sep 2007 | B2 |
7287852 | Fiala | Oct 2007 | B2 |
7293873 | Dai et al. | Nov 2007 | B2 |
7311400 | Wakil et al. | Dec 2007 | B2 |
7316713 | Zhang | Jan 2008 | B2 |
7318642 | Menezes | Jan 2008 | B2 |
7322695 | Wooley et al. | Jan 2008 | B2 |
7331668 | Azar et al. | Feb 2008 | B2 |
7338161 | Chauveau et al. | Mar 2008 | B2 |
7338165 | Dai | Mar 2008 | B2 |
7338173 | Dick et al. | Mar 2008 | B2 |
7341345 | Azar et al. | Mar 2008 | B2 |
7350916 | Hong et al. | Apr 2008 | B2 |
7357509 | Williams et al. | Apr 2008 | B2 |
7360894 | Hirohara | Apr 2008 | B2 |
7364294 | Menezes | Apr 2008 | B2 |
7364299 | Donnerhacke et al. | Apr 2008 | B2 |
7365917 | Zalevsky | Apr 2008 | B2 |
7370962 | Roffman et al. | May 2008 | B2 |
7374286 | Fujieda et al. | May 2008 | B2 |
7377638 | Gupta et al. | May 2008 | B2 |
7377647 | Della Vecchia et al. | May 2008 | B2 |
7377648 | Gross et al. | May 2008 | B2 |
7380937 | Ye et al. | Jun 2008 | B2 |
7381221 | Lang et al. | Jun 2008 | B2 |
7384143 | Hall et al. | Jun 2008 | B2 |
7387387 | Dai | Jun 2008 | B2 |
7401922 | Legerton | Jul 2008 | B2 |
7404636 | Blum et al. | Jul 2008 | B2 |
7413303 | Guilloux et al. | Aug 2008 | B2 |
7413566 | Yee | Aug 2008 | B2 |
7427134 | Bourdoncle et al. | Sep 2008 | B2 |
7434930 | Lindacher et al. | Oct 2008 | B2 |
7434936 | Dai et al. | Oct 2008 | B2 |
7436595 | Cathey et al. | Oct 2008 | B2 |
7441900 | Mihashi et al. | Oct 2008 | B2 |
7441901 | Liang | Oct 2008 | B2 |
7455407 | Neal et al. | Nov 2008 | B2 |
7460288 | Liang | Dec 2008 | B2 |
7475985 | Blum et al. | Jan 2009 | B2 |
7478907 | Somani et al. | Jan 2009 | B2 |
7481533 | Gupta et al. | Jan 2009 | B2 |
7490936 | Blum et al. | Feb 2009 | B2 |
7490937 | Ye et al. | Feb 2009 | B2 |
7491350 | Silvestrini | Feb 2009 | B2 |
7497572 | Ye et al. | Mar 2009 | B2 |
7503652 | Menezes | Mar 2009 | B2 |
7503655 | Smith et al. | Mar 2009 | B2 |
7506983 | To et al. | Mar 2009 | B2 |
7513620 | Dai | Apr 2009 | B2 |
7517083 | Blum et al. | Apr 2009 | B2 |
7517084 | Wooley et al. | Apr 2009 | B2 |
7533993 | Blum et al. | May 2009 | B2 |
7550701 | Cathey et al. | Jun 2009 | B2 |
7562982 | Lindacher et al. | Jul 2009 | B2 |
7564559 | Choo et al. | Jul 2009 | B2 |
7566133 | Yamakaji | Jul 2009 | B2 |
7572006 | Begon et al. | Aug 2009 | B2 |
7615073 | Deacon et al. | Nov 2009 | B2 |
7625086 | Wooley et al. | Dec 2009 | B2 |
7637612 | Menezes | Dec 2009 | B2 |
7637947 | Smith et al. | Dec 2009 | B2 |
7639369 | Owner-Petersen et al. | Dec 2009 | B2 |
7641337 | Altmann | Jan 2010 | B2 |
7646549 | Zalevsky et al. | Jan 2010 | B2 |
7656509 | Haddock et al. | Feb 2010 | B2 |
7656581 | Giraudet | Feb 2010 | B2 |
7659970 | Simpson et al. | Feb 2010 | B1 |
7665842 | Ho et al. | Feb 2010 | B2 |
7673990 | Esser et al. | Mar 2010 | B2 |
7677725 | Piers et al. | Mar 2010 | B2 |
7690789 | Dai et al. | Apr 2010 | B2 |
7695136 | Dai | Apr 2010 | B2 |
7701641 | Dreher et al. | Apr 2010 | B2 |
7708410 | Dai | May 2010 | B2 |
7717558 | Hong et al. | May 2010 | B2 |
7717562 | Dai | May 2010 | B2 |
7728949 | Clarke et al. | Jun 2010 | B2 |
7731365 | Catania et al. | Jun 2010 | B2 |
7738179 | Nishi | Jun 2010 | B2 |
7748847 | Dai | Jul 2010 | B2 |
7753521 | Wooley et al. | Jul 2010 | B2 |
7762668 | Dai et al. | Jul 2010 | B2 |
7766482 | Smith et al. | Aug 2010 | B2 |
7771048 | Dai et al. | Aug 2010 | B2 |
7771053 | Polland et al. | Aug 2010 | B2 |
7775665 | Dellavecchia et al. | Aug 2010 | B2 |
7776086 | Miller | Aug 2010 | B2 |
7777932 | Zalevsky et al. | Aug 2010 | B2 |
7780293 | Andino et al. | Aug 2010 | B2 |
7798640 | Chehab et al. | Sep 2010 | B2 |
7803153 | Thorn et al. | Sep 2010 | B2 |
7811320 | Werblin | Oct 2010 | B2 |
7828435 | Rehse | Nov 2010 | B1 |
7828441 | Lindacher et al. | Nov 2010 | B2 |
7832859 | Phillips | Nov 2010 | B2 |
7837325 | Wooley et al. | Nov 2010 | B2 |
7857451 | Thibos et al. | Dec 2010 | B2 |
7859769 | Zalevsky | Dec 2010 | B2 |
7862171 | Varnas et al. | Jan 2011 | B2 |
7876417 | Dowski et al. | Jan 2011 | B2 |
7883206 | Blum et al. | Feb 2011 | B2 |
7887187 | Dai | Feb 2011 | B2 |
7887531 | Bartoli | Feb 2011 | B2 |
7891810 | Legerton | Feb 2011 | B2 |
7901076 | Azar et al. | Mar 2011 | B2 |
7901077 | Dai et al. | Mar 2011 | B2 |
7905595 | Meyers et al. | Mar 2011 | B2 |
7905917 | Altmann | Mar 2011 | B2 |
7918555 | Sverdrup et al. | Apr 2011 | B2 |
7922328 | Dai et al. | Apr 2011 | B2 |
7924432 | Hess et al. | Apr 2011 | B2 |
7926940 | Blum et al. | Apr 2011 | B2 |
7931371 | Dai | Apr 2011 | B2 |
7931372 | Dai et al. | Apr 2011 | B2 |
7936522 | Zalevsky | May 2011 | B2 |
7944553 | Simpson et al. | May 2011 | B1 |
7948637 | De groot | May 2011 | B2 |
7954950 | Dreher et al. | Jun 2011 | B2 |
7957059 | Unsbo | Jun 2011 | B2 |
7972000 | Becker et al. | Jul 2011 | B2 |
7976577 | Silvestrini | Jul 2011 | B2 |
7977385 | Karageozian et al. | Jul 2011 | B2 |
7988289 | Chehab et al. | Aug 2011 | B2 |
7992997 | Varnas | Aug 2011 | B2 |
7997725 | Phillips | Aug 2011 | B2 |
7997727 | Ho et al. | Aug 2011 | B2 |
7998198 | Angelopoulos et al. | Aug 2011 | B2 |
8002410 | Shea | Aug 2011 | B2 |
8016420 | Yee et al. | Sep 2011 | B2 |
8025400 | Chernyak | Sep 2011 | B2 |
8040604 | Zalevsky et al. | Oct 2011 | B2 |
8043370 | Bretthauer et al. | Oct 2011 | B2 |
8057038 | Dai et al. | Nov 2011 | B2 |
8061838 | Giraudet et al. | Nov 2011 | B2 |
8066767 | Fiala et al. | Nov 2011 | B2 |
8066769 | Werblin | Nov 2011 | B2 |
8079704 | Sanger | Dec 2011 | B2 |
8083759 | Cox et al. | Dec 2011 | B2 |
8087778 | Gupta et al. | Jan 2012 | B2 |
8092016 | Blum et al. | Jan 2012 | B2 |
8100527 | Hong et al. | Jan 2012 | B2 |
8113651 | Blum et al. | Feb 2012 | B2 |
8113655 | Tyrin et al. | Feb 2012 | B1 |
8118427 | Bonnin et al. | Feb 2012 | B2 |
8128222 | Portney | Mar 2012 | B2 |
8142016 | Legerton et al. | Mar 2012 | B2 |
8142017 | Drobe et al. | Mar 2012 | B2 |
8142499 | Somani et al. | Mar 2012 | B2 |
8147816 | Till et al. | Apr 2012 | B2 |
8152300 | Lindacher | Apr 2012 | B2 |
8167940 | Hong et al. | May 2012 | B2 |
8171937 | Bendett et al. | May 2012 | B2 |
8192020 | Goto et al. | Jun 2012 | B2 |
8192022 | Zalevsky | Jun 2012 | B2 |
8201941 | Choo et al. | Jun 2012 | B2 |
8201943 | Hammer et al. | Jun 2012 | B2 |
8206379 | Homer | Jun 2012 | B2 |
8215770 | Blum et al. | Jul 2012 | B2 |
8216213 | Gross et al. | Jul 2012 | B2 |
8216308 | Blake et al. | Jul 2012 | B2 |
8231673 | Sacharoff et al. | Jul 2012 | B2 |
8240850 | Apter et al. | Aug 2012 | B2 |
8241354 | Hong et al. | Aug 2012 | B2 |
8246609 | Zickler et al. | Aug 2012 | B2 |
8251509 | Dai et al. | Aug 2012 | B2 |
8256896 | Zhao | Sep 2012 | B2 |
8267515 | Azar et al. | Sep 2012 | B2 |
8277047 | Koschmieder | Oct 2012 | B2 |
8287592 | Silvestrini | Oct 2012 | B2 |
8287593 | Portney | Oct 2012 | B2 |
8297751 | Spratt et al. | Oct 2012 | B2 |
8307832 | Schroeder et al. | Nov 2012 | B2 |
8319937 | Clarke et al. | Nov 2012 | B2 |
8342683 | Payor et al. | Jan 2013 | B2 |
8342684 | Ho et al. | Jan 2013 | B2 |
8343215 | Miller et al. | Jan 2013 | B2 |
8345350 | Epple et al. | Jan 2013 | B2 |
8357196 | Jain et al. | Jan 2013 | B2 |
8366270 | Pujol et al. | Feb 2013 | B2 |
8372319 | Liguori et al. | Feb 2013 | B2 |
8377124 | Hong et al. | Feb 2013 | B2 |
8382281 | Weeber et al. | Feb 2013 | B2 |
8388130 | Legerton | Mar 2013 | B2 |
8388137 | Dreher et al. | Mar 2013 | B2 |
8393733 | Wooley et al. | Mar 2013 | B2 |
8394084 | Palankar et al. | Mar 2013 | B2 |
8403483 | Klink et al. | Mar 2013 | B2 |
8409181 | Bor | Apr 2013 | B2 |
8410162 | Garner et al. | Apr 2013 | B2 |
8419185 | Liang | Apr 2013 | B2 |
8426551 | Murakami et al. | Apr 2013 | B2 |
8430508 | Weeber | Apr 2013 | B2 |
8430511 | Legerton | Apr 2013 | B2 |
8434025 | Fisher et al. | Apr 2013 | B2 |
8444267 | Weeber et al. | May 2013 | B2 |
8454160 | Dai | Jun 2013 | B2 |
8454162 | Zhou et al. | Jun 2013 | B2 |
8454167 | Seiler et al. | Jun 2013 | B2 |
8454862 | Andino et al. | Jun 2013 | B2 |
8460376 | Donitzky et al. | Jun 2013 | B2 |
8474974 | Dai | Jul 2013 | B2 |
8480228 | Weeber | Jul 2013 | B2 |
8482858 | Sprague | Jul 2013 | B2 |
8485662 | Collins et al. | Jul 2013 | B2 |
8486055 | Knox et al. | Jul 2013 | B2 |
8486141 | Lang et al. | Jul 2013 | B2 |
8491824 | Goodenough et al. | Jul 2013 | B2 |
8496701 | Hermans et al. | Jul 2013 | B2 |
8506075 | Bandhauer et al. | Aug 2013 | B2 |
8512320 | Knox et al. | Aug 2013 | B1 |
8518028 | Brady et al. | Aug 2013 | B2 |
8521318 | Zhao | Aug 2013 | B2 |
8529058 | Hong et al. | Sep 2013 | B2 |
8529559 | Liang | Sep 2013 | B2 |
8531783 | Zalevsky et al. | Sep 2013 | B2 |
8535376 | Altmann | Sep 2013 | B2 |
8540370 | Norrby | Sep 2013 | B2 |
8545016 | Dai et al. | Oct 2013 | B2 |
8556885 | Hohla et al. | Oct 2013 | B2 |
8573775 | Weeber | Nov 2013 | B2 |
8579436 | Calixte et al. | Nov 2013 | B2 |
8591032 | Thibos et al. | Nov 2013 | B2 |
8602560 | Marin et al. | Dec 2013 | B2 |
8608800 | Portney | Dec 2013 | B2 |
8619362 | Portney | Dec 2013 | B2 |
8623081 | Canovas Vidal et al. | Jan 2014 | B2 |
8623083 | Piers et al. | Jan 2014 | B2 |
8644562 | Tosa et al. | Feb 2014 | B2 |
8646916 | Bille | Feb 2014 | B2 |
8647612 | Garner et al. | Feb 2014 | B2 |
8652205 | Hong et al. | Feb 2014 | B2 |
8662664 | Artal et al. | Mar 2014 | B2 |
8668332 | Nakajima et al. | Mar 2014 | B2 |
8668333 | Portney | Mar 2014 | B2 |
8672472 | Holden et al. | Mar 2014 | B2 |
8672473 | Martinez et al. | Mar 2014 | B2 |
8672474 | Lindacher et al. | Mar 2014 | B2 |
8672476 | Roffman et al. | Mar 2014 | B2 |
8684520 | Lindacher et al. | Apr 2014 | B2 |
8684526 | Neal | Apr 2014 | B2 |
8685006 | Wiechmann et al. | Apr 2014 | B2 |
8687290 | Jahn et al. | Apr 2014 | B2 |
8690319 | Menezes | Apr 2014 | B2 |
8690942 | Rombach | Apr 2014 | B2 |
8696118 | Back | Apr 2014 | B2 |
8714741 | Donoso et al. | May 2014 | B2 |
8717547 | Gorschboth et al. | May 2014 | B2 |
8721070 | Loeb et al. | May 2014 | B2 |
8740978 | Weeber et al. | Jun 2014 | B2 |
8748818 | Own et al. | Jun 2014 | B2 |
8757800 | Esser et al. | Jun 2014 | B2 |
8764191 | Pujol et al. | Jul 2014 | B2 |
8771348 | Zhao | Jul 2014 | B2 |
8778022 | Blum et al. | Jul 2014 | B2 |
8783872 | Giraudet | Jul 2014 | B2 |
8786520 | Legerton et al. | Jul 2014 | B2 |
8789945 | Suzaki et al. | Jul 2014 | B2 |
8789947 | Collins et al. | Jul 2014 | B2 |
8795706 | Garner et al. | Aug 2014 | B2 |
8801176 | Roffman et al. | Aug 2014 | B2 |
8801781 | Tabernero et al. | Aug 2014 | B2 |
8820927 | Weeber | Sep 2014 | B2 |
8827449 | Dai | Sep 2014 | B2 |
8827452 | Zhou et al. | Sep 2014 | B2 |
8830377 | Marks et al. | Sep 2014 | B2 |
8833936 | Varnas | Sep 2014 | B2 |
8833940 | Yee et al. | Sep 2014 | B2 |
8844823 | Fritz et al. | Sep 2014 | B2 |
8851670 | Dai et al. | Oct 2014 | B2 |
8852273 | Hong et al. | Oct 2014 | B2 |
8852274 | Doraiswamy et al. | Oct 2014 | B2 |
8858626 | Noy | Oct 2014 | B2 |
8862447 | Weeber | Oct 2014 | B2 |
8864306 | de Juan, Jr. et al. | Oct 2014 | B2 |
8864307 | Tung | Oct 2014 | B2 |
8864824 | Silvestrini et al. | Oct 2014 | B2 |
8882264 | Bradley et al. | Nov 2014 | B2 |
8882268 | Calixte et al. | Nov 2014 | B2 |
8885139 | Peyghambarian et al. | Nov 2014 | B2 |
8888277 | Jubin et al. | Nov 2014 | B2 |
8888279 | Legerton et al. | Nov 2014 | B2 |
8894203 | Bradley et al. | Nov 2014 | B2 |
8894204 | Weeber et al. | Nov 2014 | B2 |
8894208 | Legerton | Nov 2014 | B2 |
8894706 | Portney | Nov 2014 | B2 |
8899746 | Back | Dec 2014 | B2 |
8900296 | Holliday et al. | Dec 2014 | B2 |
8906089 | Piers et al. | Dec 2014 | B2 |
8911079 | Roffman et al. | Dec 2014 | B2 |
8911086 | Dai | Dec 2014 | B2 |
8911496 | Jacobson et al. | Dec 2014 | B2 |
8913331 | Zalevsky et al. | Dec 2014 | B2 |
8926092 | Weeber | Jan 2015 | B2 |
8931897 | Holden et al. | Jan 2015 | B2 |
8950859 | Tung | Feb 2015 | B2 |
8950860 | Tse et al. | Feb 2015 | B2 |
8955968 | Zalevsky | Feb 2015 | B2 |
8974526 | Bogaert | Mar 2015 | B2 |
8992012 | Wooley et al. | Mar 2015 | B2 |
8998408 | Wei et al. | Apr 2015 | B2 |
9016859 | Wooley et al. | Apr 2015 | B2 |
9039172 | Lindacher et al. | May 2015 | B2 |
9195074 | Bakaraju et al. | Nov 2015 | B2 |
9201250 | Bakaraju | Dec 2015 | B2 |
9535263 | Bakaraju | Jan 2017 | B2 |
9541773 | Bakaraju | Jan 2017 | B2 |
9575334 | Bakaraju | Feb 2017 | B2 |
10209535 | Bakaraju | Feb 2019 | B2 |
10838235 | Bakaraju | Nov 2020 | B2 |
10948743 | Bakaraju | Mar 2021 | B2 |
20020035358 | Wang | Mar 2002 | A1 |
20020058996 | Silvestrini et al. | May 2002 | A1 |
20030058404 | Thorn et al. | Mar 2003 | A1 |
20030065020 | Gale et al. | Apr 2003 | A1 |
20030076478 | Cox | Apr 2003 | A1 |
20030164440 | Czarnetzki et al. | Sep 2003 | A1 |
20030199858 | Schelonka | Oct 2003 | A1 |
20040120035 | Hoffmann | Jun 2004 | A1 |
20040135968 | Morgan et al. | Jul 2004 | A1 |
20040141150 | Roffman et al. | Jul 2004 | A1 |
20040156014 | Piers et al. | Aug 2004 | A1 |
20040165147 | Della Vecchia et al. | Aug 2004 | A1 |
20040201821 | Tyson | Oct 2004 | A1 |
20040237971 | Radhakrishnan et al. | Dec 2004 | A1 |
20050041203 | Lindacher et al. | Feb 2005 | A1 |
20050099600 | Frey et al. | May 2005 | A1 |
20050124983 | Frey et al. | Jun 2005 | A1 |
20050200809 | Dreher et al. | Sep 2005 | A1 |
20050203619 | Altmann | Sep 2005 | A1 |
20050213031 | Meyers | Sep 2005 | A1 |
20050259222 | Kelch et al. | Nov 2005 | A1 |
20050261752 | Chernyak | Nov 2005 | A1 |
20060020267 | Marmo | Jan 2006 | A1 |
20060055071 | Kendig et al. | Mar 2006 | A1 |
20060055884 | Molinari et al. | Mar 2006 | A1 |
20060066808 | Blum et al. | Mar 2006 | A1 |
20060082725 | Yamaguchi et al. | Apr 2006 | A1 |
20060116762 | Hong et al. | Jun 2006 | A1 |
20060116764 | Simpson | Jun 2006 | A1 |
20060116765 | Blake et al. | Jun 2006 | A1 |
20060158611 | Piers et al. | Jul 2006 | A1 |
20060177430 | Bhushan et al. | Aug 2006 | A1 |
20060184243 | Yilmaz | Aug 2006 | A1 |
20060192310 | Lindacher et al. | Aug 2006 | A1 |
20060197908 | Legerton et al. | Sep 2006 | A1 |
20060204861 | Ben-Eliezer et al. | Sep 2006 | A1 |
20060227286 | Hong et al. | Oct 2006 | A1 |
20060235428 | Silvestrini | Oct 2006 | A1 |
20060247765 | Fedor | Nov 2006 | A1 |
20060251316 | Tucker et al. | Nov 2006 | A1 |
20060256283 | Legerton et al. | Nov 2006 | A1 |
20060271184 | Silvestrini | Nov 2006 | A1 |
20060279699 | Liang | Dec 2006 | A1 |
20070008493 | Kratzer | Jan 2007 | A1 |
20070038202 | Celestino et al. | Feb 2007 | A1 |
20070159562 | Haddock et al. | Jul 2007 | A1 |
20070159593 | Hibino et al. | Jul 2007 | A1 |
20070195276 | Plut | Aug 2007 | A1 |
20070202612 | Winter-Jensen et al. | Aug 2007 | A1 |
20070211214 | Dai | Sep 2007 | A1 |
20070255401 | Lang | Nov 2007 | A1 |
20070279585 | Bartoli | Dec 2007 | A1 |
20070282438 | Hong et al. | Dec 2007 | A1 |
20080033301 | Dellavecchia et al. | Feb 2008 | A1 |
20080033546 | Liang | Feb 2008 | A1 |
20080039937 | Obrebski | Feb 2008 | A1 |
20080079895 | Jubin et al. | Apr 2008 | A1 |
20080193504 | Menko | Aug 2008 | A1 |
20080208335 | Blum et al. | Aug 2008 | A1 |
20080212024 | Lai | Sep 2008 | A1 |
20080218687 | Phillips | Sep 2008 | A1 |
20080221674 | Blum et al. | Sep 2008 | A1 |
20080275433 | Russmann et al. | Nov 2008 | A1 |
20080297721 | Gupta et al. | Dec 2008 | A1 |
20080319428 | Wiechmann et al. | Dec 2008 | A1 |
20090015785 | Blum et al. | Jan 2009 | A1 |
20090059163 | Pinto | Mar 2009 | A1 |
20090062911 | Bogaert | Mar 2009 | A1 |
20090103044 | Duston et al. | Apr 2009 | A1 |
20090157179 | Pinto et al. | Jun 2009 | A1 |
20090160075 | Simpson et al. | Jun 2009 | A1 |
20090168015 | Wooley et al. | Jul 2009 | A1 |
20090171305 | El Hage | Jul 2009 | A1 |
20090210054 | Weeber et al. | Aug 2009 | A1 |
20090216218 | Somani et al. | Aug 2009 | A1 |
20090227677 | Garner et al. | Sep 2009 | A1 |
20090234336 | Chernyak et al. | Sep 2009 | A1 |
20090324691 | Mahadevan et al. | Dec 2009 | A1 |
20090326650 | Zickler et al. | Dec 2009 | A1 |
20090326652 | Azar | Dec 2009 | A1 |
20100004741 | Gupta et al. | Jan 2010 | A1 |
20100016965 | Hong et al. | Jan 2010 | A1 |
20100026958 | Wooley et al. | Feb 2010 | A1 |
20100036489 | Lindacher et al. | Feb 2010 | A1 |
20100057202 | Bogaert | Mar 2010 | A1 |
20100079723 | Kingston et al. | Apr 2010 | A1 |
20100087921 | Simpson | Apr 2010 | A1 |
20100094413 | Rombach et al. | Apr 2010 | A1 |
20100097569 | Weeber et al. | Apr 2010 | A1 |
20100131059 | Callahan et al. | May 2010 | A1 |
20100157240 | Schmid et al. | Jun 2010 | A1 |
20100161051 | Hong | Jun 2010 | A1 |
20100182566 | Becker et al. | Jul 2010 | A1 |
20100195044 | Collins et al. | Aug 2010 | A1 |
20100204325 | Blanda et al. | Aug 2010 | A1 |
20100204571 | Dellavecchia et al. | Aug 2010 | A1 |
20100204788 | Van noy | Aug 2010 | A1 |
20100211169 | Stanley et al. | Aug 2010 | A1 |
20100281021 | Weeber et al. | Nov 2010 | A1 |
20100315589 | Portney | Dec 2010 | A1 |
20100318186 | Bumbalough et al. | Dec 2010 | A1 |
20100324408 | Klink et al. | Dec 2010 | A1 |
20100331830 | Bischoff et al. | Dec 2010 | A1 |
20100331831 | Bischoff et al. | Dec 2010 | A1 |
20110028948 | Raksi et al. | Feb 2011 | A1 |
20110028949 | Raksi et al. | Feb 2011 | A1 |
20110029073 | Liang | Feb 2011 | A1 |
20110037942 | Lieberman et al. | Feb 2011 | A1 |
20110153248 | Gu et al. | Jun 2011 | A1 |
20110166651 | Fiala | Jul 2011 | A1 |
20110184514 | Angelopoulos et al. | Jul 2011 | A1 |
20110228226 | Pixton et al. | Sep 2011 | A1 |
20110264081 | Reich et al. | Oct 2011 | A1 |
20110270389 | Glazer et al. | Nov 2011 | A1 |
20120016352 | Dick et al. | Jan 2012 | A1 |
20120033177 | Sarver et al. | Feb 2012 | A1 |
20120033182 | Dai | Feb 2012 | A1 |
20120035598 | Stobrawa et al. | Feb 2012 | A1 |
20120041553 | Gupta et al. | Feb 2012 | A1 |
20120062836 | Tse et al. | Mar 2012 | A1 |
20120075579 | Roffman et al. | Mar 2012 | A1 |
20120075580 | Roffman et al. | Mar 2012 | A1 |
20120075581 | Roffman et al. | Mar 2012 | A1 |
20120078239 | Reinstein et al. | Mar 2012 | A1 |
20120095370 | Wanders et al. | Apr 2012 | A1 |
20120113386 | Back | May 2012 | A1 |
20120120365 | Legerton et al. | May 2012 | A1 |
20120123534 | Yoon et al. | May 2012 | A1 |
20120130486 | Yoon | May 2012 | A1 |
20120140165 | Soriano et al. | Jun 2012 | A1 |
20120140167 | Blum | Jun 2012 | A1 |
20120143325 | Christie et al. | Jun 2012 | A1 |
20120148633 | Sun et al. | Jun 2012 | A1 |
20120158131 | Angelopoulos et al. | Jun 2012 | A1 |
20120194780 | Back | Aug 2012 | A1 |
20120206692 | Yamaguchi et al. | Aug 2012 | A1 |
20120239144 | Azar | Sep 2012 | A1 |
20120245683 | Christie et al. | Sep 2012 | A1 |
20120268712 | Egan et al. | Oct 2012 | A1 |
20120271287 | Gross et al. | Oct 2012 | A1 |
20120271412 | Feingold et al. | Oct 2012 | A1 |
20120287512 | Egan et al. | Nov 2012 | A1 |
20120310223 | Knox et al. | Dec 2012 | A1 |
20120320333 | Holden et al. | Dec 2012 | A1 |
20120320334 | Ho et al. | Dec 2012 | A1 |
20120327363 | Wooley et al. | Dec 2012 | A1 |
20130010260 | Tumlinson et al. | Jan 2013 | A1 |
20130040895 | Robinson et al. | Feb 2013 | A1 |
20130046381 | Zalevsky et al. | Feb 2013 | A1 |
20130050637 | Roffman et al. | Feb 2013 | A1 |
20130050651 | Azar et al. | Feb 2013 | A1 |
20130072591 | Sandstedt et al. | Mar 2013 | A1 |
20130072917 | Kaschke et al. | Mar 2013 | A1 |
20130096544 | Donoso et al. | Apr 2013 | A1 |
20130100537 | Matthae et al. | Apr 2013 | A1 |
20130107201 | Argal et al. | May 2013 | A1 |
20130107204 | Spratt et al. | May 2013 | A1 |
20130135579 | Krug et al. | May 2013 | A1 |
20130138094 | Fabrikant | May 2013 | A1 |
20130138208 | Simonov et al. | May 2013 | A1 |
20130165911 | Raksi et al. | Jun 2013 | A1 |
20130169925 | Caldeira et al. | Jul 2013 | A1 |
20130169928 | Caldeira et al. | Jul 2013 | A1 |
20130169930 | Caldeira et al. | Jul 2013 | A1 |
20130170017 | Caldeira et al. | Jul 2013 | A1 |
20130170022 | Caldeira et al. | Jul 2013 | A1 |
20130173029 | Caldeira et al. | Jul 2013 | A1 |
20130182215 | Tung | Jul 2013 | A1 |
20130182216 | Ho et al. | Jul 2013 | A1 |
20130190735 | Hohla et al. | Jul 2013 | A1 |
20130201464 | Epple et al. | Aug 2013 | A1 |
20130204237 | Fabrikant | Aug 2013 | A1 |
20130211515 | Blum et al. | Aug 2013 | A1 |
20130222765 | Thompson et al. | Aug 2013 | A1 |
20130226162 | Knox et al. | Aug 2013 | A1 |
20130226293 | Venkateswaran | Aug 2013 | A1 |
20130235338 | Weeber | Sep 2013 | A1 |
20130242255 | Caldarise et al. | Sep 2013 | A1 |
20130245754 | Blum et al. | Sep 2013 | A1 |
20130250235 | Foulds et al. | Sep 2013 | A1 |
20130258279 | Dai | Oct 2013 | A1 |
20130261744 | Gupta et al. | Oct 2013 | A1 |
20130268071 | Vilupuru et al. | Oct 2013 | A1 |
20130278888 | Bakaraju et al. | Oct 2013 | A1 |
20130278891 | Zhao | Oct 2013 | A1 |
20130282116 | Van Der Mooren et al. | Oct 2013 | A1 |
20130289450 | Homer | Oct 2013 | A1 |
20130297015 | Johns et al. | Nov 2013 | A1 |
20130297018 | Brady et al. | Nov 2013 | A1 |
20130308094 | Mohan et al. | Nov 2013 | A1 |
20130308186 | Cathey et al. | Nov 2013 | A1 |
20130308212 | Kubala et al. | Nov 2013 | A1 |
20130335701 | Canovas Vidal et al. | Dec 2013 | A1 |
20130338767 | Mazzocchi et al. | Dec 2013 | A1 |
20130345807 | Olsen | Dec 2013 | A1 |
20140009736 | Zhao | Jan 2014 | A1 |
20140009742 | Donoso et al. | Jan 2014 | A1 |
20140022505 | Pugh et al. | Jan 2014 | A1 |
20140022508 | Ben-Yaish et al. | Jan 2014 | A1 |
20140028973 | Scolaro | Jan 2014 | A1 |
20140029102 | Zalevsky et al. | Jan 2014 | A1 |
20140036225 | Chehab et al. | Feb 2014 | A1 |
20140039361 | Yin et al. | Feb 2014 | A1 |
20140039616 | Suzaki | Feb 2014 | A1 |
20140043584 | Blum | Feb 2014 | A1 |
20140063445 | Caldarise et al. | Mar 2014 | A1 |
20140066909 | Coleman et al. | Mar 2014 | A1 |
20140081357 | Legerton et al. | Mar 2014 | A1 |
20140081395 | Weeber | Mar 2014 | A1 |
20140085726 | Portney | Mar 2014 | A1 |
20140095137 | Dai et al. | Apr 2014 | A1 |
20140098338 | Suzaki | Apr 2014 | A1 |
20140104563 | Bakaraju et al. | Apr 2014 | A1 |
20140107631 | Ferrari | Apr 2014 | A1 |
20140107777 | Portney | Apr 2014 | A1 |
20140111763 | Griffin | Apr 2014 | A1 |
20140111764 | Lai et al. | Apr 2014 | A1 |
20140113946 | Abad | Apr 2014 | A1 |
20140121769 | Canovas Vidal et al. | May 2014 | A1 |
20140125954 | Kingston et al. | May 2014 | A1 |
20140132914 | Holden et al. | May 2014 | A1 |
20140135919 | Gontijo et al. | May 2014 | A1 |
20140135921 | Robert et al. | May 2014 | A1 |
20140148737 | Homer | May 2014 | A1 |
20140155999 | Vidal Canovas et al. | Jun 2014 | A1 |
20140156000 | Campin et al. | Jun 2014 | A1 |
20140160436 | Kasthurirangan et al. | Jun 2014 | A1 |
20140160438 | Wakil et al. | Jun 2014 | A1 |
20140168602 | Weeber | Jun 2014 | A1 |
20140172092 | Carson et al. | Jun 2014 | A1 |
20140179621 | Patel et al. | Jun 2014 | A1 |
20140200211 | Abad | Jul 2014 | A1 |
20140200665 | Lang et al. | Jul 2014 | A1 |
20140204333 | Blum et al. | Jul 2014 | A1 |
20140211147 | Wei et al. | Jul 2014 | A1 |
20140211149 | Hansen | Jul 2014 | A1 |
20140218684 | Kumar et al. | Aug 2014 | A1 |
20140236134 | Wiechmann et al. | Aug 2014 | A1 |
20140240655 | Pugh et al. | Aug 2014 | A1 |
20140240656 | Pugh et al. | Aug 2014 | A1 |
20140243385 | Garner et al. | Aug 2014 | A1 |
20140243972 | Wanders | Aug 2014 | A1 |
20140247423 | Drobe | Sep 2014 | A1 |
20140247424 | Drobe | Sep 2014 | A1 |
20140257480 | Van Der Mooren et al. | Sep 2014 | A1 |
20140268034 | Wooley et al. | Sep 2014 | A1 |
20140277430 | Franssen et al. | Sep 2014 | A1 |
20140277434 | Weeber et al. | Sep 2014 | A1 |
20140277437 | Currie | Sep 2014 | A1 |
20140288538 | Sluyterman van Langeweyde | Sep 2014 | A1 |
20140293426 | Dobschal | Oct 2014 | A1 |
20140303725 | Barrett et al. | Oct 2014 | A1 |
20140308771 | Brigham et al. | Oct 2014 | A1 |
20140320800 | Collins et al. | Oct 2014 | A1 |
20140330376 | Kleinman | Nov 2014 | A1 |
20140333894 | Dai | Nov 2014 | A1 |
20140340632 | Pugh et al. | Nov 2014 | A1 |
20140362338 | de Juan, Jr. et al. | Dec 2014 | A1 |
20150022775 | Ando et al. | Jan 2015 | A1 |
20150036102 | Ghosh et al. | Feb 2015 | A1 |
20150092157 | Tessieres et al. | Apr 2015 | A1 |
20150277145 | Bakaraju et al. | Oct 2015 | A1 |
Number | Date | Country |
---|---|---|
1995039744 | Feb 1998 | AU |
2004296710 | Aug 2009 | AU |
2004269429 | Aug 2010 | AU |
2005260234 | Dec 2010 | AU |
2007258008 | May 2011 | AU |
2006301940 | Mar 2012 | AU |
2010289653 | Apr 2012 | AU |
2007212045 | May 2012 | AU |
2010319453 | May 2012 | AU |
2011223499 | Sep 2012 | AU |
2011223500 | Oct 2012 | AU |
2007281018 | Jan 2013 | AU |
2008316316 | Jan 2013 | AU |
2008316726 | Feb 2013 | AU |
2007204641 | Apr 2013 | AU |
2013203024 | May 2013 | AU |
2013206684 | Jul 2013 | AU |
2013213472 | Aug 2013 | AU |
2008254861 | Oct 2013 | AU |
2013201501 | Oct 2013 | AU |
2013231016 | Oct 2013 | AU |
2010246164 | Jan 2014 | AU |
2012283742 | Jan 2014 | AU |
2008293695 | Feb 2014 | AU |
2010246165 | Feb 2014 | AU |
2010246171 | Feb 2014 | AU |
2010308489 | Feb 2014 | AU |
2012270984 | Feb 2014 | AU |
2013211446 | Feb 2014 | AU |
2014200281 | Feb 2014 | AU |
2012291464 | Mar 2014 | AU |
2009327455 | Apr 2014 | AU |
2009330163 | May 2014 | AU |
2014202701 | Jun 2014 | AU |
2011284783 | Jul 2014 | AU |
2013202694 | Aug 2014 | AU |
2014200420 | Aug 2014 | AU |
2013232736 | Oct 2014 | AU |
2013243237 | Oct 2014 | AU |
2014201288 | Oct 2014 | AU |
2014224341 | Nov 2014 | AU |
2012244130 | Dec 2014 | AU |
2014262297 | Dec 2014 | AU |
2012273287 | Mar 2015 | AU |
2013332247 | Apr 2015 | AU |
2015201867 | Apr 2015 | AU |
2530787 | Dec 2004 | CA |
2545390 | Jun 2005 | CA |
101315467 | Dec 2008 | CN |
101686802 | Mar 2010 | CN |
101566727 | Dec 2010 | CN |
102323658 | Jan 2012 | CN |
104049381 | Sep 2014 | CN |
104094164 | Oct 2014 | CN |
104094165 | Oct 2014 | CN |
101981489 | Nov 2014 | CN |
103257458 | Feb 2015 | CN |
104375283 | Feb 2015 | CN |
102722037 | Mar 2015 | CN |
102004063091 | Jul 2006 | DE |
102006045838 | Apr 2008 | DE |
102006053117 | May 2008 | DE |
102006053118 | May 2008 | DE |
102006053120 | May 2008 | DE |
102008049401 | Apr 2010 | DE |
102009009382 | Aug 2010 | DE |
0732608 | Sep 1996 | EP |
1080387 | Mar 2001 | EP |
0746272 | Oct 2001 | EP |
1188076 | Mar 2002 | EP |
1196807 | Apr 2002 | EP |
1046075 | Jun 2002 | EP |
1229876 | Aug 2002 | EP |
1001720 | Oct 2002 | EP |
1284685 | Feb 2003 | EP |
0958513 | Aug 2003 | EP |
1347328 | Sep 2003 | EP |
1285305 | Nov 2003 | EP |
1264204 | May 2005 | EP |
1546791 | Jun 2005 | EP |
1639399 | Mar 2006 | EP |
1740346 | Jan 2007 | EP |
1750633 | Feb 2007 | EP |
1805552 | Jul 2007 | EP |
1667612 | Dec 2008 | EP |
2021914 | Feb 2009 | EP |
2043556 | Apr 2009 | EP |
2043558 | Apr 2009 | EP |
1562467 | Jul 2009 | EP |
2076810 | Jul 2009 | EP |
2088978 | Aug 2009 | EP |
1567907 | Sep 2009 | EP |
2094193 | Sep 2009 | EP |
2106566 | Oct 2009 | EP |
2115519 | Nov 2009 | EP |
1381908 | Aug 2010 | EP |
1188091 | Oct 2010 | EP |
2278387 | Jan 2011 | EP |
2334260 | Jun 2011 | EP |
2403429 | Jan 2012 | EP |
2425294 | Mar 2012 | EP |
1991151 | Apr 2012 | EP |
2113226 | Jul 2012 | EP |
2363097 | Sep 2012 | EP |
2590594 | May 2013 | EP |
2616876 | Jul 2013 | EP |
2642332 | Sep 2013 | EP |
2415425 | Jan 2014 | EP |
2440962 | Aug 2014 | EP |
2765952 | Aug 2014 | EP |
2806827 | Dec 2014 | EP |
2813882 | Dec 2014 | EP |
2018594 | Apr 2015 | EP |
2421464 | Sep 2013 | ES |
2406381 | Apr 2014 | ES |
2803922 | Jul 2001 | FR |
2430047 | Jan 2009 | GB |
2000089173 | Mar 2000 | JP |
2003015093 | Jan 2003 | JP |
04528049 | Aug 2010 | JP |
04807696 | Nov 2011 | JP |
2012093522 | May 2012 | JP |
05225641 | Jul 2013 | JP |
2013130659 | Jul 2013 | JP |
2013180135 | Sep 2013 | JP |
05346503 | Nov 2013 | JP |
2013250351 | Dec 2013 | JP |
2013250352 | Dec 2013 | JP |
2014074866 | Apr 2014 | JP |
101063989 | Sep 2011 | KR |
20130003645 | Jun 2013 | KR |
101390215 | Apr 2014 | KR |
20140138756 | Dec 2014 | KR |
147361 | Nov 2012 | MY |
147454 | Dec 2012 | MY |
102810 | Apr 2006 | SG |
112309 | Apr 2007 | SG |
112312 | Aug 2007 | SG |
173191 | Sep 2011 | SG |
169355 | Jul 2014 | SG |
176940 | Jul 2014 | SG |
178588 | Jan 2015 | SG |
2014006936 | Feb 2015 | SG |
WO 2001035880 | May 2001 | WO |
WO 2001047449 | Oct 2001 | WO |
WO 2001089424 | Nov 2001 | WO |
WO 2003040807 | May 2003 | WO |
WO 2004068214 | Aug 2004 | WO |
WO 2005001553 | Jan 2005 | WO |
WO 2005006060 | Jan 2005 | WO |
WO 2005050291 | Jun 2005 | WO |
WO 2005124433 | Dec 2005 | WO |
WO 2006018834 | Feb 2006 | WO |
WO 2006066816 | Jun 2006 | WO |
WO 2006088440 | Aug 2006 | WO |
WO 2007010806 | Jan 2007 | WO |
WO 2007047427 | Apr 2007 | WO |
WO 2009029481 | Mar 2009 | WO |
WO 2009029515 | Mar 2009 | WO |
WO 2009032626 | Mar 2009 | WO |
WO 2009076670 | Jun 2009 | WO |
WO 2009101202 | Aug 2009 | WO |
WO 2009140080 | Nov 2009 | WO |
WO 2010009254 | Jan 2010 | WO |
WO 2010009257 | Jan 2010 | WO |
WO 2010017129 | Feb 2010 | WO |
WO 2010051172 | May 2010 | WO |
WO 2010071751 | Jun 2010 | WO |
WO 2010100523 | Sep 2010 | WO |
WO 2010123618 | Oct 2010 | WO |
WO 2011028659 | Mar 2011 | WO |
WO 2011035033 | Mar 2011 | WO |
WO2011049642 | Apr 2011 | WO |
WO 2011090591 | Jul 2011 | WO |
WO 2012054651 | Jun 2012 | WO |
WO 2012127538 | Sep 2012 | WO |
WO 2012154597 | Nov 2012 | WO |
WO 2013015743 | Jan 2013 | WO |
WO 2013018379 | Feb 2013 | WO |
WO 2013093916 | Jun 2013 | WO |
WO 2013098870 | Jul 2013 | WO |
WO2013101793 | Jul 2013 | WO |
WO 2013113798 | Aug 2013 | WO |
WO 2013118499 | Aug 2013 | WO |
WO 2013123558 | Aug 2013 | WO |
WO 2013134825 | Sep 2013 | WO |
WO 2013136361 | Sep 2013 | WO |
WO 2013149303 | Oct 2013 | WO |
WO 2013154768 | Oct 2013 | WO |
WO 2013184239 | Dec 2013 | WO |
WO 2014008904 | Jan 2014 | WO |
WO 2014014521 | Jan 2014 | WO |
WO 2014027689 | Feb 2014 | WO |
WO 2014015234 | Mar 2014 | WO |
WO 2012138426 | Apr 2014 | WO |
WO 2014050879 | Apr 2014 | WO |
WO 2014062883 | Apr 2014 | WO |
WO 2014064163 | May 2014 | WO |
WO 2014064210 | May 2014 | WO |
WO 2014085352 | Jun 2014 | WO |
WO 2014091529 | Jun 2014 | WO |
WO 2014089612 | Jun 2014 | WO |
WO 2014111831 | Jul 2014 | WO |
WO 2014120928 | Aug 2014 | WO |
WO 2014124493 | Aug 2014 | WO |
WO 2014128033 | Aug 2014 | WO |
WO 2014128035 | Aug 2014 | WO |
WO 2014128744 | Aug 2014 | WO |
WO 2014135986 | Sep 2014 | WO |
WO 2014156607 | Oct 2014 | WO |
WO 2014167425 | Oct 2014 | WO |
WO 2014174067 | Oct 2014 | WO |
WO 2014177388 | Nov 2014 | WO |
WO 2014177389 | Nov 2014 | WO |
WO 2014184399 | Nov 2014 | WO |
WO 2014185136 | Nov 2014 | WO |
WO 2014198972 | Dec 2014 | WO |
Entry |
---|
US 7,780,728 B2, 08/2010, Hong et al. (withdrawn) |
International Search Report dated May 20, 2013 for PCT/AU2013/000354. |
Patent Examination Report No. 1 for AU2013202694 dated May 17, 2013. |
Legras et al. “Through-Focus Visual Performance Measurements and Predictions with Multifocal Contact Lenses” Vision Research 50, p. 1185-1193 (2010). |
Bakaraju, Ravi Chandra, “Optical Performance of Simultaneous Vision Multifocal Contact Lenses Using Schematic and Physical Eye Models” PhD Thesis (Sep. 2010). |
Yi, Fang, “Wavefront Aberrations and the Depth of Focus of the Human Eye” PhD Thesis (2010). |
Charman, W.N., J.A. Jennings, and H. Whitefoot, The refraction of the eye in the relation to spherical aberration and pupil size. Br J Physiol Opt, 1978. 32: p. 78-93. |
Millodot, M. and J. Sivak, Contribution of the cornea and lens to the spherical aberration of the eye. Vision Res, 1979. 19(6): p. 685-7. |
Campbell, C.E., The effect of spherical aberration of contact lens to the wearer. Am J Optom Physiol Opt, 1981. 58(3): p. 212-7. |
Cox, I. and B.A. Holden, Soft contact lens-induced longitudinal spherical aberration and its effect on contrast sensitivity. Optom Vis Sci, 1990. 67(9): p. 679-83. |
Rivolta, C., Depth of focus of optical systems with a small amount of spherical aberration. Appl Opt, 1990. 29(22): p. 3249-54. |
Gu, M. and C.J. Sheppard, Effects of defocus and primary spherical aberration on three-dimensional coherent transfer functions in confocal microscopes. Appl Opt, 1992. 31(14): p. 2541-9. |
Plakitsi, A. and W.N. Charman, Ocular spherical aberration and theoretical through-focus modulation transfer functions calculated for eyes fitted with two types of varifocal presbyopic contact lens. Cont Lens Anterior Eye, 1997. 20(3): p. 97-106. |
Legras, R., N. Chateau, and W.N. Charman, Assessment of just-noticeable differences for refractive errors and spherical aberration using visual simulation. Optom Vis Sci, 2004. 81(9): p. 718-28. |
Marsack, J.D., et al., On-eye performance of custom wavefront-guided soft contact lenses in a habitual soft lens-wearing keratoconic patient. Journal of Refractive Surgery, 2007. 23(9): p. 960. |
Preussner, P.R., Spherical and chromatic aberration in aspherical IOLs. J Cataract Refract Surg, 2007. 33(10): p. 1676; author reply 1676-7. |
Beiko, G., Spherical aberration and depth of focus. Ophthalmology, 2008. 115(9): p. 1641; author reply 1641-2. |
Guo, H., D.A. Atchison, and B.J. Birt, Changes in through-focus spatial visual performance with adaptive optics correction of monochromatic aberrations. Vision Res, 2008. 48(17): p. 1804-11. |
Gambra, E., et al., Accommodative lag and fluctuations when optical aberrations are manipulated. Journal of Vision, 2009. 9(6): p. 4. |
Pieh, S., et al., In vitro strehl ratios with spherical, aberration-free, average, and customized spherical aberration-correcting intraocular lenses. Invest Ophthalmol Vis Sci, 2009. 50(3): p. 1264-70. |
Rae, S.M., et al., Increasing negative spherical aberration with soft contact lenses improves high and low contrast visual acuity in young adults. Ophthalmic Physiol Opt, 2009. 29(6): p. 593-601. |
Theagarayan, B., et al., The effect of altering spherical aberration on the static accommodative response. Ophthalmic Physiol Opt, 2009. 29(1): p. 65-71. |
Wang, J.M., et al., Precipitation of process-derived impurities in non-Protein A purification schemes for antibodies. BioPharm International, Oct. 2009, Supp. Downstream Processing 2010: Embracing Innovation: p. 4. |
Artal, P., et al., Visual effect of the combined correction of spherical and longitudinal chromatic aberrations. Optics express, 2010. 18(2): p. 1637-1648. |
Bakaraju, R.C., et al., Inherent ocular spherical aberration and multifocal contact lens optical performance. Optom Vis Sci, 2010. 87(12): p. 1009-22. |
Benard, Y., N. Lopez-Gil, and R. Legras, Subjective depth of field in presence of 4th-order and 6th-order Zernike spherical aberration using adaptive optics technology. J Cataract Refract Surg, 2010. 36(12): p. 2129-38. |
Castignoles, F., M. Flury, and T. Lepine, Comparison of the efficiency, MTF and chromatic properties of four diffractive bifocal intraocular lens designs. Optics express, 2010. 18(5): p. 5245-5256. |
Jansonius, N.M., Spherical aberration and other higher-order aberrations in the human eye: from summary wave-front analysis data to optical variables relevant to visual perception. J Opt Soc Am A Opt Image Sci Vis, 2010. 27(5): p. 941-50. |
Legras, R., Y. Benard, and H. Rouger, Through-focus visual performance measurements and predictions with multifocal contact lenses. Vision Res, 2010. 50(12): p. 1185-93. |
Lopez-Gil, N. and V. Fernandez-Sanchez, The change of spherical aberration during accommodation and its effect on the accommodation response. J Vis, 2010. 10(13): p. 12. |
Benard, Y., N. Lopez-Gil, and R. Legras, Optimizing the subjective depth-of-focus with combinations of fourth- and sixth-order spherical aberration. Vision Res, 2011. 51(23-24): p. 2471-7. |
Gonzalez-Galicia, M.A., et al., Effects of primary spherical aberration, coma, astigmatism, and field curvature on the focusing of ultrashort pulses: Gaussian illumination and experiment. J Opt Soc Am A Opt Image Sci Vis, 2011. 28(10): p. 1990-4. |
Petelczyc, K., et al., Strehl ratios characterizing optical elements designed for presbyopia compensation. Optics express, 2011. 19(9): p. 8693-8699. |
Wu, Y. and B.C. Jiang, The effects of spherical aberration on static accommodative responses in emmetropes and myopes. Ophthalmic Physiol Opt, 2011. 31(6): p. 595-602. |
Yi, F., D.R. Iskander, and M. Collins, Depth of focus and visual acuity with primary and secondary spherical aberration. Vision Res, 2011. 51(14): p. 1648-58. |
Gallego, A.A., et al., Visual Strehl performance of IOL designs with extended depth of focus. Optom Vis Sci, 2012. 89(12): p. 1702-7. |
Gong, X.H., et al., Visual and optical performance of eyes with different corneal spherical aberration implanted with aspheric intraocular lens. Int J Ophthalmol, 2012. 5(3): p. 323-8. |
Hickenbotham, A., P. Tiruveedhula, and A. Roorda, Comparison of spherical aberration and small-pupil profiles in improving depth of focus for presbyopic corrections. J Cataract Refract Surg, 2012. 38(12): p. 2071-9. |
Legras, R., Y. Benard, and N. Lopez-Gil, Effect of coma and spherical aberration on depth-of-focus measured using adaptive optics and computationally blurred images. J Cataract Refract Surg, 2012. 38(3): p. 458-69. |
Fernandez, D., et al., Multifocal intraocular lens providing optimized through-focus performance. Opt Lett, 2013. 38(24): p. 5303-6. |
Thibos, L.N., et al., Spherical aberration and the sign of defocus. Optom Vis Sci, 2013. 90(11): p. 1284-91. |
Xu, R., A. Bradley, and L.N. Thibos, Impact of primary spherical aberration, spatial frequency and Stiles Crawford apodization on wavefront determined refractive error: a computational study. Ophthalmic Physiol Opt, 2013. 33(4): p. 444-55. |
Zheleznyak, L., et al., Modified monovision with spherical aberration to improve presbyopic through-focus visual performance. Invest Ophthalmol Vis Sci, 2013. 54(5): p. 3157-65. |
Bradley, A., et al., Influence of spherical aberration, stimulus spatial frequency, and pupil apodisation on subjective refractions. Ophthalmic Physiol Opt, 2014. 34(3): p. 309-20. |
Charman, W.N., Developments in the correction of presbyopia I: spectacle and contact lenses. Ophthalmic and Physiological Optics, 2014. 34(1): p. 8-29. |
Ramos-Lopez, D., A. Martinez-Finkelshtein, and D.R. Iskander, Computational aspects of the through-focus characteristics of the human eye. J Opt Soc Am A Opt Image Sci Vis, 2014. 31(7): p. 1408-15. |
Ruiz-Alcocer, J., et al., Optical performance of two new trifocal intraocular lenses: through-focus modulation transfer function and influence of pupil size. Clin Experiment Ophthalmol, 2014. 42(3): p. 271-6. |
Schwarz, C., et al., Binocular visual acuity for the correction of spherical aberration in polychromatic and monochromatic light. J Vis, 2014. 14(2). |
Villegas, E.A., et al., Extended depth of focus with induced spherical aberration in light-adjustable intraocular lenses. Am J Ophthalmol, 2014. 157(1): p. 142-9. |
Zheleznyak, L., H. Jung, and G. Yoon, Impact of pupil transmission apodization on presbyopic through-focus visual performance with spherical aberration. Invest Ophthalmol Vis Sci, 2014. 55(1): p. 70-7. |
International Search Report for PCT/AU2013/001137, ISA/AU, Woden ACT, dated Dec. 23, 2013. |
Judgment Granting Patent Owner's Request for Adverse Judgment, IPR 2018-00665, U.S. Pat. No. 9,195,074, Nov. 29, 2018. |
Decision on Institution of Inter Partes Review of U.S. Pat. No. 9,195,074, IPR 2018-00665, Aug. 28, 2018. |
Petition for Inter Partes Review of U.S. Pat. No. 9,195,074 including exhibits 1001-1017, IPR 2018-00665, Feb. 16, 2018. |
Number | Date | Country | |
---|---|---|---|
20210191157 A1 | Jun 2021 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16226263 | Dec 2018 | US |
Child | 17069549 | US | |
Parent | 15399445 | Jan 2017 | US |
Child | 16226263 | US | |
Parent | 14565062 | Dec 2014 | US |
Child | 15399445 | US | |
Parent | 13857613 | Apr 2013 | US |
Child | 14565062 | US |